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ABSTRACT 
 
Fetal Testosterone and Early Autism Spectrum Disorder Related  
Neurodevelopmental Outcomes 
Bo Y. Park, MPH 
Craig J. Newschaffer, PhD 
Aims: Despite widely acknowledged sex bias in Autism Spectrum Disorders (ASD), the 
underlying mechanisms are largely unknown.  The goal of this dissertation was to 
examine whether differences in prenatal testosterone levels are a possible mechanism 
underlying the observed ASD sex difference. This was accomplished through three 
specific aims. First, meconium was examined as a novel prenatal androgen matrix to 
compare androgen levels across alternate matrices obtained at the delivery time point.  
Second, the association between cord blood testosterone and ASD-related 12 month 
phenotype was estimated in a high ASD risk cohort of multiplex families.  Last, we 
investigated the relationship between widely used antimicrobials product use with 
potential androgenic activity and early autistic phenotypes.  
Methods: Studies were based in the Early Autism Risk Longitudinal Investigation 
(EARLI) cohort, an enriched risk cohort following pregnant mothers who previously had 
a child with ASD diagnosis. Prenatal information on potential exposures, confounders, 
effect modifiers and two relevant biologic samples, cord blood and meconium, and early 
ASD-related behavioral phenotypes in the children born into the cohort were available for 
analysis.  
Results: Testosterone (T) sex difference was observed in both cord blood and meconium 
and there was weak correlation between cord blood and meconium androgens. Umbilical 
cord blood T had a weak positive association with ASD related phenotype at 12 months. 
We found that the association of prenatal testosterone and early ASD-related phenotype 
varied by the sex of older child with ASD (proband). 12 month autistic traits were 
unrelated to either prenatal or postpartum use of products that contain TCS or TCC. 
Conclusion: Meconium and cord blood were both good media to measure prenatal 
androgen levels may be capturing different prenatal exposure windows. The association 
of prenatal testosterone early ASD-related phenotype was substantially different by 
proband sex indicating that androgen mediated mechanisms might be more important in 
families with female ASD in the pedigree. We found no evidence of an association 
between exposure to TCS/TCC and early ASD-related phenotype.  
  
 
OVERVIEW 
 
Introduction 
The CDC estimates that 1 in 68 US children had an autism spectrum disorder 
(ASD) in 2010 (Centers for Disease Control and Prevention, 2014).  The observed male 
to female prevalence ratio of roughly 4:1 is consistent with the vast majority of other 
epidemiologic studies around the world over the last several decades.  Given the fact that 
this striking epidemiologic feature of ASD has long been acknowledged (Newschaffer et 
al., 2007), the sex prevalence difference is underplayed in discussions of candidate 
etiologic mechanisms.  Although some mechanisms potentially driving this disparity 
have been ruled out (e.g., major X-linked risk genes (Gong et al., 2008)), an explicit 
focus on potential etiologic pathways consistent with this sex difference should be a 
priority in attempts to elucidate ASD causal mechanisms.  
 Impaired social interaction and communication are characteristics associated with 
ASD.   These characteristics have also long been recognized as sexually dimorphic traits 
in typical development (Manson, 2008; Wallen, 2009), although debate continues around 
the exact magnitude, nature and generalizability of differences.   Nonetheless, Baron 
Cohen (2002) has gone on to hypothesize that ASD may in fact be an extreme 
manifestation of male brain (Baron-Cohen, 2002).   Androgens, such as testosterone, 
have an established role in fetal brain development and differentiation (Kimura, 
Okanoya, & Wada, 1999; Peper & Koolschijn, 2012).  Fetal gonads and adrenal glands 
play the major role in prenatal androgen production (Baron-Cohen, Lutchmaya, & 
  
 
Knickmeyer, 2004; Blackburn, 2007) as early pregnancy placental androgen production 
is quickly surpassed by developing fetal organs with only low amounts of maternal 
androgen passively diffusing across the placenta (Atkinson, Campbell, Cawood, & 
Oakey, 1996; Sun et al., 2012). Elevated prenatal testosterone levels are associated with 
sex differences in play behavior (van de Beek, van Goozen, Buitelaar, & Cohen-Kettenis, 
2009), spatial abilities (Chapman et al., 2006) and language difficulties (Keelan et al., 
2012) and defeminization of sex-typical play has been observed among girls diagnosed 
with ASD (Knickmeyer, Wheelwright, & Baron-Cohen, 2008). Although ASDs etiology 
is known to have a substantive genetic component (Jorde et al., 1991; Rosenberg et al., 
2009), findings from neuropathology, brain gene expression, and twin and sibling 
concordance and recurrence studies indicate that environmental factors are also likely 
have also likely have a substantive impact on ASD risk (Amaral, Schumann, & Nordahl, 
2008; Gronborg, Schendel, & Parner, 2013; Sandin et al., 2014). Therefore, investigation 
of environmental influences on pathways involving prenatal testosterone should also be a 
priority.  
AIMS 
The aims of this dissertation are to evaluate meconium, baby‟s first stool, as a prenatal 
androgen matrix and to evaluate fetal testosterone dependent ASD using early ASD-
related behavioral phenotypes in children born into the EARLI (Early Autism Risk 
Longitudinal Investigation) cohort.   
Three specific hypotheses were evaluated: 
  
 
Study I:  Fetal testosterone levels can be measured in meconium as well as cord blood 
and the sex difference in fetal testosterone is observable in both meconium and cord 
blood.   
Study II:  Fetal testosterone level is associated with early ASD-related phenotype. 
Study III:  Maternal prenatal triclosan/triclocarban-containing product use is associated 
with early ASD-related phenotype in the child.  
 
Theses hypotheses were tested by pursuing the following Specific Aims: 
Aim 1: Characterize meconium and cord blood as matrices for fetal testosterone 
measurement.  
1a. Compare fetal testosterone levels as measured in umbilical cord blood and 
meconium.    
1b. Contrast gender differences in fetal testosterone as measured in cord blood 
and in meconium. 
Aim 2: Estimate the association between fetal testosterone levels in cord blood and ASD-
related behaviors (measured principally by the AOSI total score) at 12 months.    
Aim 3:  Estimate the association between prenatal TCS/TCC containing product use and 
ASD-related behaviors (measured principally by the AOSI total score) at 12 months.  
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CHAPTER 1. BACKGROUND 
 
1.1 Autism Spectrum Disorders 
 
 Autism spectrum disorders (ASD) are a group of complex and pervasive 
neurodevelopmental disorders emerging early in development distinguished by impaired 
social interaction and social communication and the presence of repetitive or stereotypic 
interests, behavior and activities as core characteristics. The wide range of expression and 
severity of ASD symptoms adds to the challenge of unraveling the complex causal 
mechanism of ASD.  An ASD diagnosis is based on clinical observations of behaviors or 
symptoms and currently there is no biologic diagnostic test (Newschaffer et al., 2007).  
ASD may also coexist with varying degrees of cognitive impairments and seizure 
disorders (Schmitz & Rezaie, 2008). The existence of genetic component to ASD 
etiology is well documented (Rosenberg et al., 2009). However, findings from 
neuropathology and twin and sibling concordance and recurrence risk studies suggest that 
environmental influences during prenatal period also have a measurable impact on ASD 
risk (Hallmayer et al., 2011).  
1.12 The ASD Phenotype 
 
 A psychiatrist, Dr. Leo Kanner, first used the term "autistic" in a 1943 publication 
to describe children with characteristics similar to how we define classical autism today 
(Kanner, 1971). In the following year, Dr. Hans Asperger published his own encounter of 
children with “autistic psychopathy”(Asperger & Asperger, 1991). These groundbreaking 
reports by Dr. Kanner and Dr. Asperger shaped the pervasive developmental disorder 
  
 
now described as autism or autism spectrum disorder.  The term „autism spectrum 
disorder‟ captures the wide range of impairment severity among individuals with autism.  
In May 2013 the new Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5) defined autism under a single category (McPartland, Reichow, & 
Volkmar, 2012). The DSM-5 has two symptom domains of ASD: social/communicative 
deficits and restricted repetitive behaviors (McPartland et al., 2012).  The diagnosis of 
ASD is made using either International Classification of Disease (ICD) or Diagnostic and 
Statistical Manual of Mental Disorders (DSM) criteria. Currently, the two gold standard 
assessment tools based on DSM criteria are the Autism Diagnostic Observation Schedule 
(ADOS) (Lord et al., 2000) and the revised Autism Diagnostic Interview (ADI-R) (Lord, 
Rutter, & Le Couteur, 1994).   
A recent review described 11 different quantitative measures of ASD related 
phenotypes for infant, children and adolescents (Lai, Lombardo, & Baron-Cohen, 2014).   
Of these, the Quantitative Checklist for Autism in Toddlers (Q-CHAT), childhood autism 
screenning test (CAST), and Autism Spectrum Quotient (AQ) for children and 
adolescents are parent or caregiver reported short questionnair (25-50 item) that are 
frequently used to measure autistic traits among 18 months to 16 years old children (Lai 
et al., 2014).  The Autism Observation Scale in Infants (AOSI) is another brief 
observational quantitative assessment of infants engaged in semi-structured play and 
systematic presses to assess various autistic traits at 12 months of age (Bryson, 
Zwaigenbaum, McDermott, Rombough, & Brian, 2008).  The AOSI is a direct 
observation by trained personnel compared to other instruments that utilize parent or self 
report. 
  
 
 The estimated prevalence of autism in the US increased markedly from 5 per 
10,000 in the 1970s (Newschaffer et al., 2007) to 147 per 10,000 in 2010 (Centers for 
Disease Control and Prevention, 2014). This increasing prevalence trend has also been 
observed in other parts of the world.  A UK study showed an increase in autism incidence 
from 1989 (0.3 per 10,000) to 1999 (2 per 10,000) (Duchan & Patel, 2012). Similarly, a 
study in Taiwan observed the prevalence of ASD increase from 1.7 per 10,000 in 1996 to 
28.7 per 10,000 in 2005 (Chien, Lin, Chou, & Chou, 2011). This increase in prevalence 
worldwide may be partially attributed to changes in diagnostic criteria, increase in 
awareness and younger age of diagnosis (Elsabbagh et al., 2012; Fombonne, 2009).  
Increased awareness of ASD among both lay public and clinicians has been, to some 
extent, driven by growing knowledge of ASD etiology. Nonetheless, some increase in 
ASD prevalence driven by increased risk factors cannot be ruled out.   
The sex imbalance in ASD has been consistently observed across countries 
worldwide,  ranging from 1.33:1 to 15.7:1 with generally referenced ratio of 4 to1 
(Fombonne, 2009). Impaired social interaction and communication associated with ASD 
have been compared to sexually dimorphic traits in typical development (Manson, 2008; 
Wallen, 2009), however, debate continues around the exact magnitude, nature and 
generalizability of these sex differences.  The sex disparity in ASD will be further 
described in greater detail below.  
 Multiple comorbid disorders are frequently observed in individuals with ASD 
(Lai et al., 2014).  Some of the major behavioral or developmental comorbidities include, 
intellectual disability (40-80%), language deficiencies (50-63%, based on DSM-IV), 
  
 
anxiety (42-84%), attention problems (28-59%), sleep disruption (50-80%) and sensory 
differences (80-90%) (Lai et al., 2014; Levy, Mandell, & Schultz, 2009).  Furthermore, 
medical comorbidities such as gastroesophageal reflux (8-59%), food selectivity (30-
90%), and seizures (5-49%) have substantial financial and psychological impact on the 
family in addition to managing ASD (Lai et al., 2014; Levy et al., 2009). The lifelong 
morbidity and comorbidity associated with ASD pose a great public health concern.  The 
most recent estimate of direct and indirect costs associated with supporting an individual 
with ASD and intellectual disability over the lifespan (based on 2013 literature review) 
was $2.2 million and $1.4 million for without intellectual disability (Buescher, Cidav, 
Knapp, & Mandell, 2014). 
1.2 Neuropathology 
 ASD affects brain function and has been associated with structural anomalies in 
the brain.  Atypical postnatal enlargement in total brain volume followed by growth arrest 
in an early childhood has been observed among children diagnosed with ASD (Amaral, 
Schumann, & Nordahl, 2008) through magnetic resonance imaging (MRI). This growth 
surge may be a consequence of abnormal cell division and apoptosis regulation 
underlying ASD; however, excessive glial cell growth and inflammation have also been 
hypothesized as being part of the causal pathway leading to ASD (Amaral et al., 2008). 
Abnormal growth in a wide range of brain regions including the frontal and temporal 
cortices, frontal cortex, fusiform gyrus, amygdala and cerebellum have been observed in 
individuals with ASD (Polsek, Jagatic, Cepanec, Hof, & Simic, 2011). Atypical 
activation, sensitivity and growth have been observed in these areas among people with 
ASD (Dichter, 2012; Polsek et al., 2011).  Some hypothesize that rapid formation of brain 
  
 
cells may also leave insufficient time for experience-dependent brain maturation and 
specialization in ASD patients (Polsek et al., 2011). It has been hypothesized that 
disturbances in normal brain development during the first 6 months of gestation could 
result in numerous diverse abnormal brain morphologies and highlights the potential 
importance of the prenatal period in ASD etiology (Schmitz & Rezaie, 2008). 
 Autopsy studies of individuals with ASD observed abnormalities in brain regions 
and neurons. Increased cell count was observed in the prefrontal cortex, which is a region 
critical to planning complex cognitive behavior, decision making and moderating social 
behavior (Yang & Raine, 2009). However,  smaller cell size and reduced density was 
observed in the Purkinje cells, one of the largest neurons in the human brain located in 
the cerebellum (Ritvo et al., 1986). In addition, increases in numbers, density, and 
activation of microglia, a type of macrophages present in brain and spinal cord was 
observed among individuals with ASD (Morgan et al., 2010).   
Functional magnetic resonance imaging (fMRI) detects enhanced synaptic 
transmission signals based on blood flow (Pina-Camacho et al., 2012). The fMRI method 
has been used in ASD research to detect regional brain activation and functional 
connectivity (Pina-Camacho et al., 2012). Brain regions potentially associated with ASD 
related social (fusiform gyrus, amygdala) and ritualistic behaviors (anterior cingulate 
cortex) have been identified using fMRI (Pina-Camacho et al., 2012).  The wide range of 
structural and functional abnormalities observed in individual brain with ASD suggests 
that multiple regions of the brain could be involved in ASD etiology.  
 
  
 
1.3 Genetic Risk Factors 
 There is strong evidence that genetic factors play substantial role in ASD risk. 
ASD heritability has been studied since the 1970s (Newschaffer et al., 2007) in 
monozygotic (MZ) and dizygotic (DZ) twin pairs.  Monozygotic twins are genetically 
identical at the DNA sequence level whereas dizygotic twins share genetic similarities 
comparable to siblings but have the same prenatal environment during their fetal 
development.  The MZ concordance is used to assess heritability and MZ concordance 
less than 100% indicate that non-shared environment influences (e.g. those influences 
epigenetic processes and gene expression) play a role. To date, there have been seven 
studies reporting MZ concordance of ASD ranging from 36-95% with comparison DZ 
concordance s ranging from 0-23%. The most recent, and largest, twin concordance study 
of 37,570 twin pairs reported pairwise ASD concordance of MZ and DZ as 54% and 
25%, respectively (Sandin et al., 2014). Another study characterized ASD-related 
phenotypes in 192 twin pairs and reported sex stratified ASD concordance in males as 
77% for MZ pairs and 31% in DZ pairs (Hallmayer et al., 2011).  Sibling recurrence in 
families who already have one affected child have been previously reported as ranging 
from 3-25% (Ozonoff et al., 2011; Sandin et al., 2014).  The higher concordance reported 
in DZ twins compared to recurrence in non-twin siblings suggests that the shared prenatal 
environment may also play a role in ASD risk.   
 Given the high heritability of ASD, genetic markers of ASD have been explored 
in numerous studies seeking to identify specific ASD risk genes (Geschwind, 2011). 
Initially, ASD was assumed to be caused by a relatively small number of genes having a 
large effect. However, studies over the past decade have made it clear that ASD is 
  
 
genetically (Geschwind, 2011) as well as clinically heterogeneous. Genome-wide 
association studies (GWAS), whole genome sequencing, and whole exome sequencing 
with microarray technology have identified hundreds of ASD-associated genes, some rare 
with large effect (rare variant), and some common with small effect (common variant) 
(Geschwind, 2011). Common variants with small effects have been explored (such as 
receptor tyrosine kinase MET, Cadherin 9 and 10, semaphorin-5A), however, such 
approaches have struggled to provide replicable results (State & Levitt, 2011).   Fragile X 
Syndrome, Tuberous Sclerosis, Timothy Syndrome, and Phelan-McDermid Syndrome 
are rare inherited conditions caused by de novo mutations and have been associated with 
increased ASD risk. These genetic studies of rare conditions have identified Neuroligins, 
SHANK3, and Neurexin 1 as ASD risk genes (State & Levitt, 2011).  Copy number 
variations (CNVs), large-scale deletions or duplications of chromosome regions, have 
emerged recently as rare variations in ASD.  Among ASD cases which do not have 
identified genetic mutations, 5-10% may have CNVs (Buxbaum et al., 2012; Devlin & 
Scherer, 2012). It is evident that heritability is an important component in ASD etiology. 
However, incomplete MZ concordance, symptom variation among MZ concordant pairs, 
greater DZ concordance than sibling recurrence, and neuropathology with prenatal origin 
all indicate that environmental factors have a measurable impact on ASD etiology.  
 The effect of environmental exposure may depend on an individual‟s genotype. 
Gene-environmental interaction is present when the association between environmental 
exposure and the outcome depends on the genotype of an individual. Only a few studies 
have addressed joint ASD risk resulting from specific combinations of genotypes and 
environmental exposures (Schmidt et al., 2011; Volk et al., 2014). One study assessed 
  
 
interaction between air pollution and genotype found that air pollution exposure has 
increased ASD risk among individuals with variant in the MET receptor tyrosine kinase 
gene (Volk et al., 2014).  Another paper explored interaction of vitamin usage and 
functional genetic variants involved in one-carbon metabolism by decreasing ASD risk 
and found that protective effect of vitamin usage was greater among mothers with gene 
variants involved in one-carbon metabolism (Schmidt et al., 2011).  
1.4 Non-heritable Risk Factors 
1.41 Parental age 
 Advanced parental age at conception may pose increased risk of ASD as de novo 
genetic alteration becomes more likely. A recent meta-analysis of 16 studies found that 
ASD risk increased by 50% for children born to mothers greater than 35 years old 
compared to those born to mothers between 25 and 29 years old (Sandin et al., 2012). 
Similar meta-analysis of 12 studies on paternal age reported that comparing to fathers age 
≤29 years, the odds ratios of ASD in offspring was 1.22 for 30-39 year old fathers, 1.78 
for 40-49 old fathers and 2.46 for ≥50 year old fathers (Hultman, Sandin, Levine, 
Lichtenstein, & Reichenberg, 2011).  
1.42 Obstetric, perinatal and neonatal factors 
 
 Numerous studies have examined the association between ASD risk and obstetric, 
perinatal and neonatal factors. A recent meta-analysis of 60 prenatal risk factor studies 
reported associations with birth order (1st vs. ≥3rd), gestational diabetes, bleeding, and 
maternal immigration (Gardener, Spiegelman, & Buka, 2009). Another review and meta-
  
 
analysis includes that the most robust perinatal and neonatal risk factors in ASD were 
abnormal presentation, cesarean delivery, prematurity, maternal hemorrhage, low birth 
weight, small for gestational age, congenital malformation, low 5 minute Apgar score, 
hyperbilirubinemia, encephalopathy and birth defects (Gardener, Spiegelman, & Buka, 
2011; Guinchat et al., 2012).  Further, maternal hospitalization with infection during 
pregnancy (Lee et al., 2015; Zerbo et al., 2013), maternal weight gain during pregnancy 
(Bilder et al., 2013), paternal obesity (Suren et al., 2014), having longer than 5 year or 
less than 12 months inter pregnancy interval (Cheslack-Postava et al., 2014) are both 
associated with increased risk of ASD.  However, the underlying mechanisms behind the 
association of this heterogeneous group of obstetric and perinatal complications with 
ASD remain unclear.  
1.43 Teratogens 
 
 The vulnerability of the developing human brain to teratogens, such as lead and 
rubella, is well understood (Landrigan, 2010). This vulnerability is generally believed to 
be greatest during the prenatal development, especially in the first trimester of pregnancy; 
however, some teratogens have a critical impact period extending to second and third 
trimesters (Blackburn, 2007).  There is a growing body of evidence that links some 
teratogens and ASD.  Prenatal exposure to thalidomide, prescribed in 1950-1960 to treat 
primarily morning sickness among pregnant women, has been linked to increased risk of 
ASD (Newschaffer et al., 2007). Also Misoprostol, which is widely used in some parts of 
the world to induce labor and abortion, was reported as possible ASD risk factor in case 
series (Dufour-Rainfray et al., 2011; Landrigan, 2010). Children with prenatal exposure 
  
 
to valproic acid, an anticonvulsant medication, are at increased risk for developing ASD, 
with 3% of the most recent reported series of 249 exposed children having ASD as 
diagnosis (Dufour-Rainfray et al., 2011).  
 Endocrine disrupting compounds (EDCs) are exogenous chemicals that mimic 
(agonist) or interfere (antagonist) with normal hormone function, and some EDCs exhibit 
both effects. They are potential developmental teratogens since EDCs may exert action 
on brain development by binding to the hormone receptors, altering DNA methylation, 
disrupting  hypothalamic-pituitary-gonadal (HPG) axis and hypothalamic-pituitary-
thyroid (HPT) axis (Gore, 2010).  During a pregnancy, some EDCs can cross the placenta 
and affect the developing fetus (Skakkebaek et al., 2011). However, the mechanisms by 
which EDCs affect developing brain are still poorly understood.  
1.5 Sex Disparity in ASD 
 
 The first autism case series described by Dr. Kanner included 8 boys and 3 girls 
(Kanner, 1971). This sex difference continued to be observed as an ASD related feature 
over the decades. A review conducted in 1999 reported average male to female ratio of 
3.8:1 (Fombonne, 1999). Prevalence surveys since then demonstrated persisting male 
predominance from 1.3:1 to 15.7:1, with the most generally referenced ratio of 4 to 1 
(Autism, Developmental Disabilities Monitoring Network Surveillance Year Principal, 
Centers for Disease, & Prevention, 2012; Centers for Disease Control and Prevention, 
2014; Fombonne, 2003, 2009).  The specific etiologic factors underlying this pattern 
remain unclear.  However, male over-representation is not present in the subgroup of 
ASD with intellectual disability (ID) (Banach et al., 2009; Fombonne, 1999; Volkmar, 
  
 
Szatmari, & Sparrow, 1993) . This sex imbalance may reflect difficulties on 
unwillingness to diagnose ASD in females and/or the inability of current diagnostic 
criteria (ADOS and ADI-R) to capture subtle presentations of ASD females (Cheslack-
Postava & Jordan-Young, 2012).  Despite potential difficulties in detecting females with 
ASD and diagnostic bias arising from the fact that the sex imbalance in ASD has become 
conventional wisdom,  there is likely some biological component driving the male 
predominance (Baron-Cohen et al., 2011).   
One population of interest to predominance in ASD sex disparity is enriched 
autism risk cohorts of families with at least one child with ASD.   A recent enriched ASD 
risk pregnancy cohort observed a more modest sex difference of 1.65: 1 in the siblings 
(Zwaigenbaum et al., 2012). A theory behind the reduction in the sex ratio is that the 
female subjects born into the enriched risk cohort are at higher risk for developing ASD, 
leading to similar risk ratio compared to male subjects born into the cohort. This is in line 
with the “threshold model” where females have a higher threshold for developing ASD 
than males and ASD females carry a higher mutation load than ASD males (Werling & 
Geschwind, 2013).  Another explanation may be that high risk siblings receive more 
uniform surveillance of ASD identification across sexes. Given this striking 
epidemiologic feature of ASD has long been acknowledged (Newschaffer et al., 2007), 
the sex prevalence difference is underplayed in discussions of candidate pathophysiologic 
theories.  Some mechanisms that were suggested as explanations for this disparity, such 
as X-linked genes, have been largely ruled out (Gong et al., 2008).   
  
 
Sexual dimorphism in the human brain across development is a potential etiologic 
pathway consistent with this sex difference of ASD. Impaired social interaction and 
communication are core characteristics associated with ASD. These characteristics along 
with spatial ability, aggression, decreases empathy and play behavior have long been 
recognized as sexually dimorphic traits in typical development (Cohen-Bendahan, 
Buitelaar, van Goozen, Orlebeke, & Cohen-Kettenis, 2005; Manson, 2008; Wallen, 
2009), although the debate continues regarding the exact magnitude, nature and 
generalizability of these differences (Cohen-Bendahan, van de Beek, & Berenbaum, 
2005).  In light of the persistent reported sex difference in ASD prevalence, Baron Cohen 
(2002) has hypothesized that ASD may in fact be an extreme manifestation of the “male 
brain” (Baron-Cohen, 2002). Extreme male brain (EMB) theory is grounded on the 
empathizing-systemizing theory of classic psychological sex differences which suggest 
that females on average have stronger tendency to empathize (understand and share the 
feelings of another) whereas males have stronger tendency to systemize (establish rule-
based systems) (Baron-Cohen, 2002).  A recent large study of 4,700 adults showed that 
ASD-affected males had lowest empathizing ability followed by ASD-affected females, 
typically developing males and typically developing females ASD-affected males had 
highest systemizing ability followed by ASD-affected females, typically developing 
males, and typically developing females (Baron-Cohen et al., 2014).  Testosterone, the 
essential hormone responsible for sexual differentiation, (Blackburn, 2007) has been used 
as a biomarker in four studies to further explore the EMB theory in ASD etiology 
(Auyeung et al., 2012; Auyeung et al., 2009; Whitehouse, Mattes, Maybery, 
Dissanayake, et al., 2012). These are discussed further below.     
  
 
1.51 Fetal Testosterone  
 In primates, androgens, such as testosterone, are the primary hormones 
responsible for behavioral and sexual differentiation (Baron-Cohen, Knickmeyer, & 
Belmonte, 2005). Androgens, such as testosterone, have an established role in fetal brain 
development and differentiation (Kimura, Okanoya, & Wada, 1999; Peper & Koolschijn, 
2012; Swaab, Fliers, & Partiman, 1985).  Testosterone is a lipophilic molecule that passes 
through the blood brain barrier and cell membranes. Testosterone binds to androgen 
receptor (AR) in cytoplasm and enters the nucleus to affect DNA transcription.  
Moreover, neural connectivity and neural development are affected by testosterone since 
testosterone has been shown to effect programmed cell death (Baron-Cohen et al., 2005). 
Substantial AR binding occurs in the cerebral cortex, cerebellum, amygdala, corpus 
callosum and cingulate cortex of fetal primate brain in both sexes (Baron-Cohen et al., 
2005). Testosterone levels are modulated by hypothalamic-pituitary-gonadal (HPG) axis, 
receptors and enzymes (e.g. p450 protease) (Gore, 2010).  
In the fetus, the developing  gonads and adrenal glands are the predominant 
sources of androgen precursors that are then converted to androgens by the placenta 
(Baron-Cohen, Lutchmaya, & Knickmeyer, 2004; Blackburn, 2007).  The direct maternal 
contribution of androgens to the fetus is believed to be minimal as trans-placental 
diffusion of androgens is limited (Atkinson, Campbell, Cawood, & Oakey, 1996; Sun et 
al., 2012).  Developing human males experience a testosterone surge between weeks 8 
and 24 of gestation (Blackburn, 2007); however, it is difficult to get accurate measure of 
fetal testosterone in humans. It has been hypothesized that the fetal surge is responsible 
for sex differentiation of the brain, (Auyeung, Lombardo, & Baron-Cohen, 2013) 
  
 
although late gestation has also been proposed as a critical period for brain sex 
differentiation in some animal studies (Goy, Bercovitch, & McBrair, 1988; Roselli, Estill, 
Stadelman, Meaker, & Stormshak, 2011). Prenatal testosterone dependent sexual 
dimorphism of the brain is described in more detail below. In addition to the fetal surge, a 
neonatal testosterone surge also occurs during first few months after birth in males 
reaching baseline level by 6 months of age (Kuiri-Hanninen et al., 2011).     
 Fetal testosterone level affects cognitive development in typically developing 
children. Elevated fetal testosterone levels measured in amniotic fluid (Chapman et al., 
2006; Chura et al., 2010; R. Knickmeyer, Baron-Cohen, Raggatt, & Taylor, 2005; R. C. 
Knickmeyer, Wheelwright, & Baron-Cohen, 2008; van de Beek, van Goozen, Buitelaar, 
& Cohen-Kettenis, 2009) and cord blood (Whitehouse, Mattes, Maybery, Sawyer, et al., 
2012) have been associated with sex differences in play behaviors (van de Beek et al., 
2009), spatial abilities (Chapman et al., 2006; R. Knickmeyer et al., 2005), social 
difficulties (R. Knickmeyer et al., 2005), decreased empathy (Chapman et al., 2006) and 
language difficulties(Whitehouse, Mattes, Maybery, Sawyer, et al., 2012). De-
feminization of sex-typical play has been observed among girls diagnosed with ASD (R. 
C. Knickmeyer et al., 2008).  Moreover, a recent study found that increase fetal 
testosterone level was associated with increased rightward asymmetry in the brain region 
involved in language and visiospacial ability (Chura et al., 2010). The sexual dimorphism 
of the brain is hypothesized to be largely dependent on the prenatal testosterone surge. 
However, direct manipulation of hormone during human pregnancy or studies comparing 
fetal brains before and after the surge are challenging to perform as potentially unethical, 
therefore, confirmation of the exact critical window has yet to be done.     
  
 
The role of fetal androgens in ASD etiology has been explored in only a limited 
number of studies.  One study found a positive correlation between congenital adrenal 
hyperplasia (CAH), which results in antenatal overproduction of adrenal androgens, and 
the presence of autistic traits (R. Knickmeyer et al., 2006). In it, 60 CAH subjects were 
compared to 49 unaffected relatives with significantly higher autistic traits (measured 
between 12–45 years of age) observed in females with CAH compared to unaffected 
females.  To date, four cohort studies reported on prenatal testosterone levels and ASD 
related phenotypes as summarized in Table 1. Three investigations by Auyeung et al. 
found positive associations between amniotic fluid testosterone and quantitative measures 
of ASD-related behavioral phenotypes – two in younger children (12-24month of age) 
(Auyeung et al., 2012; Auyeung, Taylor, Hackett, & Baron-Cohen, 2010) and one in 
older children (6-10 years of age) (Auyeung et al., 2009).  These UK studies from the 
Cambridge Fetal Testosterone Project included subjects who received amniocentesis 
during pregnancy between 1996-2001 and 2004-2006 and were then recruited into 
cohorts for prospective follow-up.  These subjects were and mailed questionnaires 
assessing their child‟s ASD-related phenotype (using AQ-Child (Auyeung et al., 2009), 
CAST (Auyeung et al., 2009), and Q-CHAT (Auyeung et al., 2012; Auyeung et al., 
2010)) at 18 months to 10 years of age.   Response rates ranged from 33-57% of eligible 
subjects (Table 1).  
 The first study by Auyeung et al. in 2009 reported an average 11 point increase 
on both AQ-Child (150 points possible) and CAST (31 points possible) associated with 
each 1 nmol/L increase in amniotic testosterone concentration during second trimester of 
pregnancy among children between the age of 6-10 years. The CAST (Child Autism 
  
 
Spectrum Test) is a validated quantitative measure of autistic traits reported by parents. 
The AQ-Child (Child Autism Spectrum Quotient) is another parent reported measure of 
autistic traits derived from Autism Spectrum Quotient (AQ), which is a good measure of 
autistic traits across the life-span (Woodbury-Smith, Robinson, Wheelwright, & Baron-
Cohen, 2005). This study suggested prenatal testosterone as a predictor of autistic traits 
(Auyeung et al., 2009). A subsequent study using the 2004-2006 cohort also observed a 
positive association between increased in amniotic testosterone level and an ASD 
screening questionnaire (the Q-CHAT) administered at 18-24 months of age.  The Q-
CHAT (Quantitative Checklist for Autism in Toddlers) is a parent reported quantitative 
measure (100 points possible) developed to identify toddlers at risk for developing ASD.  
This study provides some evidence that traits associated with autism may be sexually 
dimorphic at 18-24 months of age (Auyeung et al., 2010).  In the third study using the 
same 2004-2006 cohort, a subset of subjects from the previous study who also had 
salivary testosterone measures collected at three month of age were used to investigate 
the role of postnatal testosterone on Q-CHAT scores. While the positive association 
between prenatal testosterone level and autistic traits persisted in this subset, no 
association was found between postnatal testosterone level and autistic traits (Spearman‟s 
rho= -0.09, not significant: p value not reported) (Auyeung et al., 2013) suggesting that 
prenatal (but not postnatal) testosterone exposure is associated with the development of 
autistic traits among 18 to 24 month olds. 
In these three studies, Auyeung et al. established prenatal testosterone as a 
potential predictor of autistic traits emerging in childhood.  However, the studies had 
limitations.  First and foremost, the study populations were limited to those who had 
  
 
clinical indications for amniocentesis, so there are questions of whether the observed 
association generalizes to children of women who do not have obstetric concerns that 
lead to amniocentesis. Additionally, the final model covariate selection was solely based 
on p-values, even when univariate analysis showed associations between sex and both 
testosterone and autistic traits.  One Australian population study using umbilical cord 
blood testosterone level (collected between 1989-1991) and autistic trait assessed using 
AQ at 19-20 years of age found no association (rho range: -0.01 to 0.06) (Whitehouse, 
Mattes, Maybery, Dissanayake, et al., 2012). However, the ASD trait assessment was 
performed when cohort members were 20 years of age and thus there had been decades 
of postnatal environmental and developmental influences on behavior in their participants 
and potential differentially greater loss-to-follow-up among more affected individuals.    
Furthermore, participants were drawn from the general population, so the expected 
prevalence of those with more extreme ASD-related traits would be very low.  All four 
studies were prospective with minimal recall bias but had low participation rates and may 
have been subject to selection biases. Association between prenatal testosterone level and 
sex difference were observed in all studies (Auyeung et al., 2012; Auyeung et al., 2009; 
Whitehouse, Mattes, Maybery, Dissanayake, et al., 2012). However, positive associations 
between prenatal testosterone level and autistic traits was only consistently observed in 
one research group using amniotic fluid (Auyeung et al., 2012; Auyeung et al., 2009), 
which is limited by high-risk pregnancies and do not represent the broader population of 
pregnant women. 
  
Table 1. Review of Four Cohort Studies Assessing Testosterone Level and Quantitative ASD Related Traits  
Author 
Year 
 (setting; n) 
Source of 
cohort 
(age) 
Testostero
ne Matrix 
(method)^ 
Testosterone 
Level by Sex  
mean; SD 
(nmol/L) (P val 
across sex) 
Results by 
ASD Measure 
(Estimate; SD;  
P val) Comments 
Auyeung  
2009 
(UK; 
n=235) 
Medical 
Records  
1996-2001 
(6-10yrs) 
 
Amniotic 
Fluid 
(RIA) 
M: 0.84; 0.4 
F: 0.32; 0.2 
(<0.001) 
AQ-C  
(11.6; 3.2;0.01) 
 
CAST  
(11.6; 3.2; 0.01) 
 *Positive associations found between amniotic 
testosterone and autistic traits.                                                               
*Parent reported autistic traits.   
*Units for final regression analysis unclear. 
*Hierarchy regression model used for covariate 
selection. 
* Adjusted for: older sibling sex, child sex and 
maternal age. 
* Response rate: 57% (AQ-C) and 54% (CAST).   
Auyeung 
2010 
(UK; 
n=129) 
Medical 
Records  
2004-2006 
(18-24mo) 
 
Amniotic 
Fluid 
(RIA) 
M: 0.82; 0.4 
F: 0.34; 0.3 
 (<0.001) 
Q-CHAT  
(7.32; 1.5;<0 .001) 
*Positive associations found between amniotic 
testosterone and autistic traits.   
*Parent reported autistic traits. 
*Hierarchy regression model used for covariate 
selection. 
* Adjusted for gestational age. 
*45% response rate. 
Auyeung 
2012 
(UK; n=35) 
Medical 
Records  
2004-2006 
(18-96mo) 
Amniotic 
Fluid and 
Saliva  
(RIA) 
M: 0.91; 0.5 
F: 0.34; 0.2 
(<0.01) 
Amniotic Fluid 
Q-CHAT  
(11.2; 3.8; <0.001) 
Saliva 
Q-CHAT  
(rho=-0.09; >0.05) 
 *Positive associations found between prenatal 
testosterone but not postnatal.   
*Parent reported autistic traits.  
*Hierarchy regression model used for covariate 
selection. 
* Adjusted for maternal age 
*33% response rate. 
Whitehouse 
2012 
(AU; 
n=374) 
Hospital 
Records 
1989-1991 
(19-20yrs) 
Umbilical 
Cord  
(LC-
MS/MS) 
M:0.49; 0.2 
F: 0.27; 0.2 
(<0.01) 
AQ  
(rho=0.01 ; 0.89) 
*Self reported autistic traits at 19-20 years of age.  
*53% response rate. 
*CAST: Childhood Autism Spectrum Test; AQ-Child: Child Autism Spectrum Quotient. ^RIA: Radio Immuno Assay; LC-MS/MS: liquid 
chromatography-tandem mass spectrometry
  
 
1.52 Biomarkers of Fetal Testosterone 
 Amniotic fluid has been considered  a favorable matrix for fetal testosterone 
measurement because the source of detected testosterone is exclusively fetal (entering 
through fetal urine (Blackburn, 2007; Judd, Robinson, Young, & Jones, 1976)) and 
because amniocentesis commonly occurs between the 11
th
 and 20
th
 weeks of pregnancy, 
capturing sample around the time when fetal testosterone is peaking in males (between 
week 12 and 18 of gestation (Abramovich, 1974)).   
 Umbilical cord blood is a more easily collected biologic sample.  However, 
testosterone levels measured in cord blood reflect fetal levels from later in gestation when 
they are below their peak.  Androgens measured in umbilical artery (UA) blood primarily 
reflecting circulating fetal androgens coming from the fetal adrenal glands and gonads 
whereas umbilical vein (UV) blood will also contain androgens from placenta 
(Blackburn, 2007).  However, one recent study comparing UA and UV androgen levels 
found that while there are absolute differences between UA and UV androgen levels, they 
are highly correlated across individuals (pearson‟s r=0.67~0.83) (Paskova et al., 2014).  
Furthermore, cord blood testosterone levels have been shown repeatedly to predictably 
differ significantly between sexes (Barry, Hardiman, Siddiqui, & Thomas, 2011; Dawood 
& Saxena, 1977; Simmons, France, Keelan, Song, & Knox, 1994).   Therefore, UA, UV 
and mixed cord blood collection approached could be conducted to obtain prenatal 
androgen levels at delivery. 
Epidemiologic studies in humans measuring cord blood testosterone concentration 
have reported associations with spatial ability (Jacklin, Wilcox, & Maccoby, 1988) and 
  
 
language development (Whitehouse, Mattes, Maybery, Sawyer, et al., 2012). The only 
published study of cord blood testosterone level and ASD-related traits reported no 
relationship (Whitehouse, Mattes, Maybery, Dissanayake, et al., 2012).  However, the 
autistic trait was subjects were 20 years of age with decades of postnatal environmental 
and developmental influences on behavior.  Cord blood is the only available biologic 
matrix capturing circulating levels of androgens and late gestation androgen levels, which 
may be an important period for brain development, could be utilized to study ASD 
etiology.    
 Meconium is a biologic matrix of some interest in the development of prenatal 
biomarkers.  It is easily collected, transported and stored.  Meconium begins forming in 
the 13th week of gestation (Bearer, 2003), conventionally around the time of the fetal 
testosterone surge.  Fetal androgens enter meconium from cycles of swallowed or inhaled 
amniotic fluid, shed epithelial cells, intestinal secretions and urine (fetal urine begins 
deposition in the amniotic fluid in the 11th gestational week). Meconium generally is not 
excreted until the delivery with complete excretion within 2 to 4 days (Newman & 
Antonakopoulos, 1989; Ortega Garcia, Carrizo Gallardo, Ferris i Tortajada, Garcia, & 
Grimalt, 2006).  Meconium accumulates throughout the pregnancy and may contain  
greater detectable amounts of low exposure compared to other biologic matrices (Marin, 
Christensen, Baer, Clark, & McMillin, 2011).    For example, recent exposure assessment 
studies utilized meconium to measure biomarkers of smoking (Braun et al., 2010; Gray et 
al., 2010), cocaine (Kwong & Ryan, 1997), alcohol (Koren, Hutson, & Gareri, 2008), 
amphetamine (Gray et al., 2009), mercury (Jiang et al., 2010),  pesticides propoxur and 
pyrethroid (Ostrea et al., 2009), phthalates (Kato, Silva, Needham, & Calafat, 2006),  and 
  
 
organophosphates (Whyatt & Barr, 2001).  However, only one study published in 1970 
reported detecting androgen in meconium (Kinsella & Francis, 1971) and meconium has 
yet to be studied as a matrix for prenatal testosterone assessment. 
1.53 Testosterone Agonists: Triclosan and Triclocarban 
 While the potential association between endogenous fetal testosterone measures 
and ASD-related phenotypes is itself of considerable etiologic interest, identifying 
modifiable exposures that influence biology through androgen-mediated mechanisms and 
ASD would, in addition to providing additional evidence supporting the role of the 
mechanism in ASD etiology, also have potential public health implications.  There are at 
this point few known environmental androgen agonists.  The phenols, triclosan (TCS) 
and triclocarban (TCC) used as broad-spectrum antimicrobial agents in personal care 
products,  are two chemicals suspected to have androgenic effect.  TCS has been shown 
to have androgen enhancing properties in aquatic species (Foran, Bennett, & Benson, 
2000; Ishibashi et al., 2004), and rodents (National Industrial Chemicals & Assessment, 
2009).  Two in vitro studies using human breast cancer cell lines found TCS to enhance 
androgenic activity through activation of androgen receptors (Christen, Crettaz, Oberli-
Schrammli, & Fent, 2010; Gee, Charles, Taylor, & Darbre, 2008).  At the same time, a 
series of in vitro analyses, while reporting TCC that itself had no androgenic properties, 
found that the chemical amplified the signaling activity of testosterone (Ahn et al., 2008).   
 These microbicides began being incorporated into personal care products in the 
US during the 1970s and their use has risen dramatically – both TCS and TCC are now 
widely used in liquid soap, toothpaste, mouth rinse, cosmetics, plastics, textiles and other 
  
 
personal care products (Ahn et al., 2008; Calafat, Ye, Wong, Reidy, & Needham, 2008).  
Widespread human exposure to TCS has been documented in the National Health and 
Nutrition Examination Survey (NHANES), with 75% of US population in 2003-04 
testing positive for some exposure in urine samples (Calafat et al., 2008).   Smaller 
studies have also detected TCS in human urine, serum, amniotic fluid and even breast 
milk (Dann & Hontela, 2011).  TCS is a chlorinated bisphenol similar to polychlorinated 
biphenyls (PCBs) (Ahn et al., 2008) and have shown to cross placental barrier (Philippat 
et al., 2013).  
Characterization of TCS and TCC exposure from commercial products can be 
estimated using biomarkers or questionnaire based self-reported product use. TCS and 
TCC biomarkers are most often measured in urine samples due to the fast excretion of the 
compound metabolites and the ease of collection (Calafat et al., 2008; Koch et al., 2014). 
Rapid elimination poses challenge because of within-individual and between-individual 
variations (Koch et al., 2014). Although biological measurement of TCS and TCC would 
be desirable, self-report of personal care product use may be used to conserve resources 
(Hong et al., 2014). Collecting ingredient list of each personal care product could reduce 
misclassification (Koch et al., 2014). No epidemiologic study has yet to investigate 
associations between TCS/TCC exposure and ASD risk.   
1.6 Conclusions  
 
There is a convergence of evidence from family studies of ASD, ASD 
nueuropathology studies, and recent gene linkage studies indicating that the prenatal 
period is critical in ASD etiology. Prenatal testosterone exposure has an established role 
  
 
in sexual dimorphism and may also be related to the development of autistic traits. A 
review of the literature on the topic of prenatal testosterone levels and ASD risk 
identified only four epidemiological studies.   Positive associations between prenatal 
testosterone level in amniotic fluid and autistic traits have been observed. Using amniotic 
fluid for testosterone measurement restricts the study population to high-risk pregnancies 
not representative of the general population of pregnant women. Thus far, autistic traits in 
these studies have been measured based on parent or self-report.   No studies have 
incorporated direct assessment of ASD traits performed by trained observers. Careful 
examination of confounding and heterogeneity of effects have yet to be incorporated, but 
may be helpful in understanding mechanisms of underlying ASD sex differences.  In the 
following chapters, I report on results of series of investigations using the Early Autism 
Risk Longitudinal Investigation (EARLI). The EARLI is a high autism risk cohort 
following pregnant mothers with older children previously diagnosed with an ASD 
(autistic disorder, Asperger syndrome or pervasive developmental disorder not otherwise 
specified) that prospectively collects extensive data on prenatal exposures (e.g. 
environmental exposure, diet, bio samples and obstetric complications). The rich prenatal 
exposure data from the EARLI study will be used to elucidate potential associations 
between prenatal androgen level and ASD risk.  
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CHAPTER 2. STUDY I: Comparison of Androgen Measurement in Umbilical Cord 
Blood and Meconium Samples 
  
 
Abstract 
Background:  Sex differences are observed in several neurodevelopmental disorders 
including Autism Spectrum Disorders (ASD). Androgens influence sex differentiation of 
the gonads as well as neural and behavioral characteristics during fetal development. The 
levels of fetal androgens fluctuate with gestational age. Previous studies have estimated 
fetal androgen levels through surrogate measures such as concentrations in amniotic fluid 
and cord blood. Meconium has not been evaluated as a matrix for quantification of 
androgens despite its ready availability. 
Study Design: Umbilical cord blood and meconium samples from 164 births in the 
EARLI (Early Autism Risk Longitudinal Investigation) cohort were used to measure fetal 
testosterone (T), androstenedione (A4) and dehyroepiandrosterone (DHEA) levels. 
Androgens were measured using liquid chromatography-tandem mass spectrometry 
assay.  
Results:  Median cord blood values for T, A4, and DHEA were 0.41 nmol/g, 1.64 nmol/g, 
and 6.51 nmol/g, respectively.  The proportions of detectable measurements were 0.89, 
0.87, and 0.99 for T, A4, and DHEA, respectively. Median meconium T, A4, and DHEA 
levels were consistently greater than cord (75 nmol/g, 647 nmol/g, and 4271 nmol/g, 
respectively). Coefficient of variation was smaller in cord blood T compared to 
meconium (0.8 and 2.3, respectively).   Testosterone level was greater in males compared 
to females in both meconium and cord blood. The largest sex differences were detected in 
meconium samples collected between 0-2 hours of birth compared to those collected later, 
although we did not have sample sequence information. The correlation between cord 
blood and meconium androgens was weak (r = -0.08~0.15). 
Conclusion: Both meconium and cord blood appear to be suitable prenatal androgen 
levels, based on evidence of detection, sex difference and variability. However, their lack 
of correlation raises questions about difference in interpretation of observed levels.   
 
Introduction 
Androgens, such as testosterone, have an established role in fetal brain 
development and differentiation (Kimura, Okanoya, & Wada, 1999; Peper & Koolschijn, 
2012; Swaab, Fliers, & Partiman, 1985).  Fetal androgen production is based on the 
cooperative efforts of several endocrine organs.  Fetal gonads and adrenal glands are the 
predominant sources of androgen precursors, which themselves have low androgenic 
  
 
activity.  The androgen precursors are then converted to androgens by the placenta 
(Baron-Cohen, Lutchmaya, & Knickmeyer, 2004; Blackburn, 2007; Dawson, 2013; 
Kallen, 2004; Paskova et al., 2014) and transferred back into fetal circulation.  There is a 
minimal amount of maternal contribution of unconjugated androgens to fetal circulating 
androgens as the placenta rapidly metabolizes and inactivates maternally derived 
hormones (Atkinson, Campbell, Cawood, & Oakey, 1996; Sun et al., 2012).   
Human males experience a testosterone surge between 8 and 24 weeks of 
gestation when sex differentiation of the brain is believed to initiate (Auyeung, 
Lombardo, & Baron-Cohen, 2013).  Sex-specific behaviors later in life are influenced by 
hormone-dependent brain differentiation occurring during specific prenatal periods as 
well as by a range of later life exposures.  Elevated fetal testosterone levels are associated 
with sex differences in play behavior (Meaney & McEwen, 1986; van de Beek, van 
Goozen, Buitelaar, & Cohen-Kettenis, 2009), spatial abilities (Chapman et al., 2006; 
Knickmeyer, Baron-Cohen, Raggatt, & Taylor, 2005), social difficulties (Knickmeyer et 
al., 2005), decreased empathy (Chapman et al., 2006) and language difficulties 
(Whitehouse et al., 2012).  
Steroids are hydrophobic molecules that become conjugated primarily by 
sulfatase enzymes in preparation for excretion (Dawson, 2013).  Circulating T and A4 
exist primarily as unconjugated molecules in umbilical cord blood; however, both 
unconjugated and conjugated DHEA are present in circulation (Paskova et al., 2014). 
There is no previous study describing the levels of unconjugated and conjugated 
androgens in meconium. In adults, the  liver plays major role in metabolizing steroids 
  
 
using sulfatase enzymes (Moscovitz & Aleksunes, 2013). Fetal liver is immature until the 
latter part of gestation (Blackburn, 2007).  However, sulfatase enzymes are expressed in 
fetal liver (Moscovitz & Aleksunes, 2013) and  placenta also plays a role in metabolizing 
steroids for elimination through urine which then will enter the amniotic fluid (Dawson, 
2013). We hypothesize that both unconjugated and conjugated androgen would be 
present in meconium and total T, A4, and DHEA levels comprising both conjugated and 
unconjugated androgens were measured in this study.  
The development of biomarkers of prenatal androgen exposure for use in 
epidemiologic research has been challenging. Amniotic fluid has been used to measure 
prenatal fetal androgen levels. However, samples are limited to those with clinical 
indications for this invasive procedure raising questions of selection bias. Alternatively, 
umbilical cord blood is easily collected but testosterone levels measured in cord blood 
reflect fetal levels in later gestation. At the same time, cord blood testosterone levels have 
consistently been shown to differ significantly between sexes (Barry, Hardiman, 
Siddiqui, & Thomas, 2011; Dawood & Saxena, 1977; Simmons, France, Keelan, Song, & 
Knox, 1994) suggesting they are capturing meaningful differences in androgen exposure.   
One of the critical periods of testosterone‟s influence on brain development has 
been assumed to coincide with the timing of the male-specific surge early in pregnancy, 
studies in nonhuman primates have also shown that levels of fetal testosterone later in 
pregnancy still independently influence sex-associated behaviors (Goy, Bercovitch, & 
McBrair, 1988),  research in and has identified late pregnancy time-windows where fetal 
testosterone influences structural and organizational changes in the brain (Roselli, Estill, 
  
 
Stadelman, Meaker, & Stormshak, 2011; Zambrano, Guzman, Rodriguez-Gonzalez, 
Durand-Carbajal, & Nathanielsz, 2014).   Consequently, cord blood may serve as a 
suitable matrix to examine prenatal androgen level and brain development.   
An alternative biologic medium of increasing interest in research on the prenatal 
period‟s influence on children outcomes is meconium. Meconium is easily collected, 
transported and stored.  It begins forming in the thirteenth week of gestation (Bearer, 
2003), around the time of fetal testosterone surge.  Fetal androgens enter meconium from 
cycles of swallowed or inhaled amniotic fluid, shed epithelial cells, intestinal secretions 
and urine (fetal urine begins deposition in the amniotic fluid in the eleventh gestational 
week) and is generally not excreted until delivery with complete excretion within 2 to 4 
days (Newman & Antonakopoulos, 1989; Ortega Garcia, Carrizo Gallardo, Ferris i 
Tortajada, Garcia, & Grimalt, 2006).  Meconium could be preferred over urine or blood 
for measuring certain prenatal endogenous and exogenous exposures due to non-invasive 
collection and longer time over which biomarkers may be integrated.  Moreover, 
meconium accumulates throughout the pregnancy and may contain  greater detectable 
amounts of low exposure compared to other biologic matrices (Marin, Christensen, Baer, 
Clark, & McMillin, 2011).  For example, recent exposure assessment studies utilized 
meconium to assess exposure to smoking (Braun et al., 2010; Gray et al., 2010), cocaine 
(Kwong & Ryan, 1997), alcohol (Koren, Hutson, & Gareri, 2008), amphetamine (Gray et 
al., 2009), mercury (Jiang et al., 2010),  pesticides propoxur and pyrethroid (Ostrea et al., 
2009), phthalates (Kato, Silva, Needham, & Calafat, 2006),  and organophosphates 
(Whyatt & Barr, 2001).  To date, only one study published in 1970 reported detecting 
  
 
androgen in meconium (Kinsella & Francis, 1971). Meconium has yet to be studied as a 
matrix for prenatal testosterone level. 
Methods 
Study Population 
The Early Autism Risk Longitudinal Investigation (EARLI) is an enriched autism 
risk cohort following pregnant mothers with older child diagnosed with ASD (autistic 
disorder, Asperger syndrome or pervasive developmental disorder not otherwise 
specified).  EARLI families were recruited at four sites (Drexel/CHOP; Johns 
Hopkins/KKI; UC Davis; and Northern CA Kaiser) in three distinct US regions 
(Southeast Pennsylvania, Northeast Maryland, Northern California).   In addition to 
having a biological child with an ASD confirmed by EARLI study clinicians, to be 
eligible mothers also had to communicate in English or Spanish and, at recruitment, meet 
the following criteria: be 18 years or older; live within 2 hours of a study site; and be less 
than 29 weeks pregnant. The design of the EARLI study is described in more detail in 
Newschaffer et al. (Newschaffer et al., 2012).   
Sample collection 
Mothers were provided with delivery sampling kits for cord blood and meconium 
collection prior to delivery. EARLI made arrangements with obstetricians, midwives, and 
birth hospital labor and delivery staff to assure sample collection and temporary storage. 
Trained nurses were instructed that blood should be collected from the umbilical vein, 
however it is likely that arterial cord blood is also collected because it is difficult to 
  
 
differentiate between umbilical vein and artery.  Androgens measured in umbilical artery 
(UA) blood primarily reflecting circulating fetal androgens coming from the fetal adrenal 
glands and gonads whereas umbilical vein (UV) blood will also contain androgens from 
placenta (Blackburn, 2007).  However, one recent study comparing UA and UV androgen 
levels found that while there are absolute differences between UA and UV androgen 
levels, they are highly correlated across individuals (pearson‟s r=0.67~0.83) (Paskova et 
al., 2014).   
 A single meconium sample was collected either at the hospital or birth center, or 
mothers, if staff were unable to obtain the sample during the delivery stay, were 
instructed to take the sample home as soon as possible and place it in their home freezer. 
Cord blood samples were collected from 192 subjects and meconium samples were 
collected from 193 subjects. Subjects missing meconium and cord blood samples (28 and 
29 respectively) were excluded from the analysis. 164 subjects had both cord blood and 
meconium samples. Variations in meconium collection time since birth was determined 
by time difference between meconium collection time and birth time (not collected) 
estimated using cord blood collection time (n=143) and placenta collection time if cord 
blood collection time was not available (n=20).  Estimated meconium collection time 
since birth was categorized into quartiles (0-2 hours, 3-6 hours, 7-10 hours, and 11+ 
hours) to assess variability of meconium androgen levels by collection time. 
Unconjugated cord blood androgen measurement 
Umbilical cord androgen levels were analyzed in 164 cord blood samples.  
Testosterone (T), androstenedione (A4) and dehyroepiandrosterone (DHEA) and internal 
  
 
standards 
2
H3-testosterone (
2
H3-T) and 19-
2
H3-androstenedione (
2
H3-A4) were extracted 
from cord blood using liquid-liquid extraction. T, A4, DHEA, 
2
H3-T and 
2
H3-A4 were 
measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay 
and a calibration curve linear across the range of the samples as previously described 
(CPR Pharma Services Pty Ltd, Thebarton, SA) (Keelan et al., 2012).  Limit of 
quantification (LOQ) was specified as a minimum signal-to-noise ratio of at least 5:1, 
with quality controls at the LOQ successfully quantified within 20% of its nominal 
concentration.   
Total meconium androgen measurement 
Total androgen (unconjugated and conjugated) levels were analyzed in 164 
meconium EARLI samples. T, A4, DHEA and internal standards (
13
C3-T, 
\13
C3-A4, and 
2
H5-DHEA) were extracted from approximately 50mg of each meconium sample by 
methanol, hexane:dicholoromethane (3:2), followed by derivatization with Girard P 
reagent as previously described (Rangiah, Shah, Vachani, Ciccimaro, & Blair, 2011). The 
sample was then used in liquid chromatography-high resolution mass spectrometry (LC-
MS/HRMS) analysis.  LOQ was defined as 10 times the lowest point on the calibration 
curve.  In 9 samples, T was below LOQ with no other analytes were below the LOQ in 
any samples.  Detailed meconium androgen extraction and quantification methods are 
available in the Methods Appendix.  Hydration variability was assessed by freeze drying 
wet meconium samples. 20 meconium samples were randomly selected from each 
collection time quartile (four random samples 1st to 3rd quartile and 8 random samples 
from fourth quartile) and freeze dried to calculate percent weight loss. 
  
 
Statistical data analysis 
The relationship between cord blood and meconium androgens were evaluated 
using Spearman‟s correlations.  LOQ for cord blood measurements were 0.12, 0.25, 2.45 
(nmol/L), for T, A4, and DHEA, respectively. LOQ for meconium measurement was 2.4 
nmol/g for total T and A4. Specific weight of blood at room temperature (1.06g/mL) was 
used to convert cord blood units to nmol/g (Trudnowski & Rico, 1974).  Samples with 
below LOQ were replaced with estimate of the expected value of levels below LOQ 
using the formula LOQ/√   (Hornung, 1990).  Sex differences were tested using t-tests 
on log-transformed androgen levels. Spearman‟s rank correlations were used to assess the 
relationship between cord blood and meconium androgens. Coefficient of variation was 
calculated using (3
rd
 quartile-1
st
 quartile)/median to account for skewed distribution of 
androgens.  All analyses were performed using STATA 12 (StataCorp., 2011.).  
Results 
 
Demographic characteristics of the study population are described in Table 1. 
Mean number of hours since birth was 6.7 with range from 0 to 23.  Around 10 percent of 
the cord blood T and DHEA were below LOQ, 0.16 nmol/g and 3.27 nmol/g, 
respectively. Females had a greater proportion of T measuring below LOQ and males had 
a higher proportion of DHEA measuring below LOQ (Table 2).  Geometric means of 
cord blood values for T, A4, and DHEA were 0.41 nmol/g, 1.64 nmol/g, and 6.51 nmol/g, 
respectively.   
  
 
Geometric mean meconium total (unconjugated and conjugated) T, A4, and 
DHEA levels were consistently greater than cord blood (75 nmol/g, 647 nmol/g, and 
4271 nmol/g, respectively) (Table 2).  Testosterone levels were greater in males 
compared to females in both cord blood (P<0.0001) and meconium (P=0.005) (Table 2 & 
3). The magnitude of the testosterone sex difference was 100 times higher in meconium 
(male to female geometric mean difference of 49 nmol/g) compared to the cord blood 
(male to female geometric mean difference 0.3 nmol/g)  (Table 2). Levels of cord blood 
A4 were higher in males; however, levels of DHEA were on average higher in females 
(Table 2).  No sex difference was observed in A4 and DHEA in meconium (Table 3). 
Coefficient of variation was smaller in cord blood compared to meconium T (0.8 and 2.3, 
respectively) and DHEA (0.9 and 2.6, respectively) and similar in A4 (0.5 and 0.7, 
respectively) (Table 9).  
Moderate correlations between androgens were observed within the matrices 
(Spearman ρ =0.2~ 0.6) with similar correlations observed when stratified by sex (Table 
4). There was only weak correlation between cord blood unconjugated androgens and 
meconium total androgens (Spearman ρ = -0.06~0.22) with similar correlations seen 
when stratified by sex (Table 5).   
Meconium collection time  
Meconium total T level and meconium collection hour since birth showed no 
correlation in females (ρ=0.04, P=0.7) but negative correlation (ρ=-0.2, P=0.06) in males 
(Appendix Figure 3).  Highest geometric mean testosterone level was observed among 
earliest collected meconium samples in males and latest collected samples in females 
  
 
(Table 6). Geometric mean testosterone sex differences were observed in meconium 
samples collected during 0-2 hours ,3-6 hours and 7-10 hours  but not in and 11+ hours 
(Figure 2).  Geometric means of total androstenedione and DHEA remained stable across 
collection time quartiles and also by sex (Table 7 and 8).  
Cord blood androgen levels have been reported to vary by gestational age 
(Paskova et al., 2014), however, variability in meconium is unknown. We observed weak 
correlation between meconium total androgens and gestational age (Spearman ρ =  -0.08~ 
-0.03). Weak correlations were also observed between cord blood unconjugated 
androgens and meconium total androgens (ρ = -0.05~0.3) when stratified by gestational 
age quartiles (Appendix Table 3).  Negligible differences in wet versus dry meconium 
weight (0.7 ~ 0.8 % mass lost) were observed regardless of collection time (Appendix 
Table 4). 
Discussion 
 
We measured and compared androgen levels in umbilical cord blood and 
meconium among children at high risk for Autism Spectrum Disorder (ASD).  Low 
correlations were found between meconium and cord blood androgen levels indicating 
that meconium and cord blood may be capturing androgen levels over different time-
windows during pregnancy. Meconium also reflects a combination of unconjugated and 
conjugated androgen from sources such as gastrointestinal excretion and ingestion of 
amniotic fluid whereas cord blood is a snapshot of circulating serum androgens which are 
mostly unconjugated.   
  
 
Sex differences in cord blood testosterone levels were consistent with several 
previously reported studies (Keelan et al., 2012; Kuijper, Ket, Caanen, & Lambalk, 2013). 
Sex differences were also found in testosterone concentration in meconium with observed 
differences greater in meconium than cord blood.  The greater observed difference may 
reflect the cumulative nature of testosterone in meconium, allowing for the capture 
testosterone close to the surge that occurs between 12-20 weeks of gestation in males. 
 The cumulative potential of meconium reflecting prenatal testosterone fluctuation 
is observed when testosterone levels are categorized into quartiles of collection time since 
birth. This may also be the result of postnatal hydration, as later samples may be more 
dilute due to increasing fluid intake, however, were negligible in our subsample analysis.  
In females, highest androgen levels are observed in meconium samples collected after 11
 
hours since birth.  Increased total androgen levels among females in late meconium 
samples may be reflecting maturing gastrointestinal system.  However, we did not have 
information on sequence of meconium samples (first, second, etc.) and it is unclear 
whether androgen level difference observed by sample collection time is due to sample 
sequence variation (capturing varying exposure window) or individual variation (similar 
sequence of sample but individual variation in parturition). 
The EARLI cord blood samples did not differentiate between umbilical artery 
(UA), umbilical vein (UV) and would most likely contain both. While androgens in the 
umbilical artery (UA) primarily reflects circulating fetal androgens from fetal adrenal and 
gonad, those in umbilical vein (UV) predominantly captures androgen levels in the 
placenta (Blackburn, 2007). However, a recent study comparing UA and UV androgen 
  
 
levels found that they are highly correlated (r=0.67~0.83) (Paskova et al., 2014). 
Furthermore, birth time was not available in the EARLI study and cord blood and 
placenta collection time which occurred very close to delivery was used as a proxy.   
Based on this study, both meconium and cord blood appear to be potentially 
useful matrices for studying prenatal androgen level. Greater testosterone sex differences 
and variability was observed in meconium samples. These suggest that meconium could 
capture signals of biologically relevant differences and have potential to observe 
meaningful differences across groups. Future studies utilizing meconium as prenatal 
biomarker of exposure should collect multiple sequential samples with collection date 
and time along with birth time. Our study also suggests that meconium is a time-
dependent cumulative marker where collection time could be an indicator of time of 
exposure.  In this study meconium collection time was broken up into quartile to assess 
changes but more meaningful breakdown could be employed for each study.   This would 
enable meconium sample restriction to better reflect etiologic window of exposure to 
reduce bias.    
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TABLES 
 
Table 1. Demographic characteristics of the 164 study participants.  
Characteristics Mean SD (min – max) 
Mother's age at delivery 33.9 4.4 (23-45) 
Gestational age 39.3 1.5 (30-42.4) 
Meconium collection time (hours since birth)^ 6.5 5.4 (0-23) 
   
 
% n 
Male 55 164 
Education  
 
163 
  <9th 2 
  High school graduation 6 
  College degree 64 
  Graduate/Professional degree 28 
 Race 
 
153 
White 65 
 Black 11 
 Asian 13 
 Other 10 
 Hispanic 17 155 
^n= 144 
 
  
  
 
Table 2. Cord blood unconjugated testosterone (T), androstenedione (A4), 
dehydroepiandrostenedione (DHEA) levels (nmol/g) by sex. 
Sex Androgen N<LOQ GM 
(nmol/g) 
GSD 
 
IQR 
Total  
(n=164) 
T 18 0.4 1.9 0.3-0.6 
A4 1 1.7 1.5 1.4-2.2 
DHEA 21 6.8 2.0 4.7-10.9 
Female* 
(n=73) 
T 15 0.3 1.8 0.2-0.4 
A4 0 1.7 1.8 1.4-2.1 
DHEA 4 8.4 1.9 6.3-11.9 
Male 
(n=91) 
T 3 0.6 1.8 0.4-0.7 
A4 1 1.7 1.6 1.5-2.3 
DHEA 17 5.9 2.0 3.9-9.7 
*Test of sex difference of GM using t-test. T: P<0.0001, A4: P=0.33, and DHEA: P=0.001; 
LOQ=limit of quantification; GM= geometric mean; GSD=geometric standard deviation; 
IQR=inter-quartile range. 
 
 
  
  
 
Table 3. Meconium total testosterone (T), androstenedione (A4), 
dehydroepiandrostenedione (DHEA) levels (nmol/g) by sex. 
Sex Androgen N<LOQ GM 
(nmol/g) 
GSD 
 
IQR 
Total  
(n=164) 
T 9 75 5 28-202 
A4 1 647 2 473-912 
DHEA 0 4271 4 1555-12547 
Female* 
(n=73) 
T 6 51 5 15-144 
A4 1 609 2 460-925 
DHEA 0 4352 4 1557-12605 
Male 
(n=91) 
T 3 100 5 29-237 
A4 0 677 2 486-881 
DHEA 0 4192 3 1554-12489 
*Test of sex difference of GM using t-test. T: P=0.005, A4: P=0.44, and DHEA: P=0.89; 
LOQ=limit of quantification; GM= geometric mean; GSD=geometric standard deviation; 
IQR=inter-quartile range 
 
 
 
  
  
 
Table 4. Spearman rank correlation of androgens within cord blood and meconium by sex  
  
All subjects  
(n=164) 
Male  
(n=73) 
Female  
(n=91) 
 Matrix 
T-
A4 
A4-
DHEA 
DHEA-
T 
T-
A4 
A4-
DHEA 
DHEA-
T 
T-
A4 
A4-
DHEA 
DHEA-
T 
Cord 0.4* 0.5* 0.2* 0.3* 0.6* 0.3* 0.6* 0.5* 0.6* 
Meconium 0.3* 0.2* 0.4* 0.4* 0.2* 0.4* 0.2* 0.2* 0.4* 
* p value <0.05 
 
 
 
Table 5. Spearman rank correlation of androgens between cord blood and meconium by 
sex  
    Meconium Total Androgens 
  
All subjects  
(n=164) 
Male  
(n=73) 
Female  
(n=91) 
  Androgens T A4 DHEA T A4 DHEA T A4 DHEA 
Cord Blood 
Unconjugated 
Androgens 
T 0.05 0.06 -0.06 -0.1 -0.06 -0.09 0.09 0.18 0.11 
A4 0.16* 0.15* 0.05 0.1 0.17 0.16 0.24* 0.11 -0.10 
DHEA 0.05 0.22* 0.03 0.04 0.12 0.07 0.13 0.31* -0.06 
*p value <0.05 
  
  
 
Table 6. Meconium testosterone (T) level (nmol/g) by collection time quartile and sex. 
Collection 
Time 
Quartiles 
All subjects 
(n=144)   
Female 
(n=63)   
Male 
(n=81) 
 n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD 
0-2 hrs 39 103.3 4.9 
 
18 57.9 5.5 
 
21 169.7 3.9 
3-6 hrs 47 52.4 3.4 
 
22 32.2 3.2 
 
25 80.4 3.0 
7-10 hrs 29 66.2 4.3 
 
11 48.7 4.1 
 
18 79.9 4.4 
11+ hrs 29 94.5 7.4   12 98.8 6.4  17 91.6 8.7 
N<LOQ: Female (n=5): 0-2 hrs (n=2), 3-6 hrs (n=1), 7-10 hrs (n=1), 11+ hrs (n=1); ^Male (n=3): 
7-10 hrs (n=1), 11+ hrs (n=2) 
 
 
 
 
 
  
  
 
Table 7. Meconium androstenedione (A4) level (nmol/g) by collection time and sex.  
Collection 
Time 
Quartiles 
All subjects 
(n=144)   
Female 
(n=63)   
Male 
(n=81) 
  
n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD 
0-2 hrs 39 695.6 1.7 
 
18 668.4 1.6 
 
21 719.8 1.8 
3-6 hrs 47 699.3 1.6 
 
22 656.8 1.9 
 
25 738.9 1.4 
7-10 hrs 29 460.3 3.4 
 
11 329.8 5.9 
 
18 564.3 2.0 
11+ hrs 29 699.7 1.7   12 727.7 1.5  17 680.6 1.9 
N<LOQ: Female (n=1): 0-2 hrs (n=1) 
 
 
  
  
 
Table 8. Meconium dehydroepiandrostenedione (DHEA) level (nmol/g) by collection 
time and sex. 
Collection 
Time 
Quartiles 
All subjects 
(n=144)   
Female 
(n=63)   
Male 
(n=81) 
 
n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD  n GM 
(nmol/g) 
GSD 
0-2 hrs 39 5477.1 4.0 
 
18 4993.9 4.7 
 
21 5928.5 3.7 
3-6 hrs 47 4770.6 3.3 
 
22 5036.9 3.5 
 
25 4547.8 3.2 
7-10 hrs 29 4191.8 3.7 
 
11 5231.9 4.0 
 
18 5496.1 3.6 
11+ hrs 29 4982.9 4.2   12 7103.1 4.7  17 3879.7 3.9 
 
 
 
 
Table 9. Variation coefficient of cord blood and meconium androgens. 
 
Meconium Cord Blood 
 T 2.33 0.79 
A4 0.68 0.47 
DHEA 2.57 0.86 
 
  
  
 
FIGURES 
 
Figure 1. Geometric mean testosterone level (nmol/g) in meconium by collection time 
(hours since birth) and sex (n=144; Male=81, Female=63).  
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APPENDIX 
 
Figure A1. Meconium androgens transformation considerations 
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Figure A1. Meconium androgens transformation considerations (continued) 
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Table A2. Spearman‟s correlation of cord blood and meconium by meconium collection 
time since birth (hour). 
  
Meconium  
   Female  Male 
 
Cord 
Blood  T A4 DHEA T A4 DHEA 
First 2 hrs T 0.29 0.35 0.18 -0.28 -0.04 0.04 
  A4 0.28 0.06 0.21 -0.32 0.06 0.12 
  DHEA 0.01 0.33 0.02 -0.4* -0.04 0.14 
3-6hrs T -0.12 0.24 -0.13 0.21 0.10 -0.06 
  A4 -0.02 0.25 0.16 -0.21 0.17 0.14 
  DHEA 0.06 0.23 -0.45* 0.06 0.28 -0.04 
7-10hrs T -0.29 -0.72* -0.74* -0.13 -0.18 -0.04 
  A4 0.08 0.07 -0.25 -0.22 -0.12 -0.01 
  DHEA -0.07 -0.33 -0.38 -0.06 0.22 0.10 
11+hrs T -0.07 0.00 0.08 -0.20 -0.32 0.33 
  A4 -0.10 -0.14 0.13 0.05 0.02 0.40 
  DHEA 0.17 -0.15 -0.52 0.14 0.15 0.39 
*P <0.05 
  
  
 
Figure A2. Relationship between meconium testosterone level (log scale) and meconium 
collection time since birth (hour). 
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Figure A3. Geometric mean meconium androstenedione level (nmol/g) by collection time 
and sex (n=144; Male=81, Female=63). 
 
 
 
 
Figure A4. Geometric mean DHEA level (nmol/g) in meconium by collection time and 
sex (n=144; Male=81, Female=63). 
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Table A3. Androgen correlation between meconium and cord blood by gestational age 
quartiles. 
  Gestational age 
  
Q1 
(n=44) 
Q2 
(n=31) 
Q3 
(n=51) 
Q4 
(n=39) 
T (rho, P val) 0.1, 0.4 0.2, 0.2 -0.1, 0.6 -0.04, 0.8 
A4 (rho, P val) 0.3, 0.03 0.3, 0.1 0.1, 0.5 0.1, 0.5 
DHEA (rho, P val) 0.1, 0.7 0.01, 1.0 -0.05, 0.7 0.1, 0.4 
 
 
 
  
  
 
Table A4. Percent mass lost in meconium freeze dry by meconium collection time 
quartile. 
Meconium Collection Time 
 Quartile  hour % Mass lost in Dry 
QT1 0 0.75 
QT1 1 0.78 
QT1 1 0.78 
QT1 2 0.67 
QT2 4 0.74 
QT2 5 0.74 
QT2 5 0.81 
QT2 6 0.73 
QT3 8 0.70 
QT3 8 0.75 
QT3 8 0.81 
QT3 9 0.74 
QT4 12 0.65 
QT4 12 0.68 
QT4 13 0.68 
QT4 15 0.70 
QT4 19 0.70 
QT4 21 0.78 
QT4 22 0.74 
QT4 23 0.69 
  
 
CHAPTER 3. STUDY II: Umbilical Cord Blood Androgen Levels and ASD-Related 
Phenotypes at 12 Months 
  
 
Abstract 
Background:  Autism spectrum disorder (ASD) is a major public health concern. In the 
United States, it affects more than 1% of children in all racial, ethnic, and socioeconomic 
groups. The male-to-female prevalence ratio of roughly 4:1 in ASD is a well-recognized 
but poorly-understood phenomenon. An explicit focus on potential etiologic pathways 
consistent with this sex difference may help elucidate causes of ASD.    
Study Design:  Umbilical cord blood from 175 births in the EARLI (Early Autism Risk 
Longitudinal Investigation) cohort that follows mothers of a child with ASD at the start 
of a subsequent pregnancy through to ASD assessment in the child, were used to measure 
fetal testosterone (T), androstenedione (A4) and dehyroepiandrosterone (DHEA) levels. 
These androgens were measured using a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) assay. Linear regression models were used to determine 
association between androgen levels in cord blood at birth and AOSI (Autism 
Observational Scales in Infants) scores at 12 months. 
Results:  An increase in T from the first quartile median to the fourth quartile median was 
associated with an average 1 point increase in AOSI score (P 0.06). Siblings of older 
ASD probands who were female had magnitude of associations between T and AOSI 
score that were six times greater than those for sibling of older male probands (test of 
interaction  P=0.02).  
 Conclusion: Among high risk infant siblings, umbilical cord blood T has a positive 
association with ASD related phenotype at 12 months. This effect is stronger when the 
older affected sibling is female.  
 
  
  
 
Introduction 
The CDC estimates that 1 in 68 US eight year old children were diagnosed with 
autism spectrum disorder (ASD) in 2010 (Centers for Disease Control and Prevention, 
2014).   The observed male to female prevalence ratio of roughly 4:1 is consistent with 
the vast majority of other epidemiologic studies around the world (Fombonne, 2009). 
Given the fact that this striking epidemiologic feature of ASD has long been 
acknowledged (Newschaffer et al., 2007), the sex prevalence difference is underplayed in 
discussions of candidate pathophysiologic theories.  Some mechanisms that suggested as 
explanations for this disparity, such as X-linked genes, have been largely ruled out (Gong 
et al., 2008).  However, an explicit focus on potential etiologic pathways consistent with 
this sex difference remains a priority in elucidating causes of ASD.  
Impaired social interaction and communication are characteristics associated with 
ASD.   These characteristics have also long been recognized as sexually dimorphic traits 
in typical development (Manson, 2008; Wallen, 2009), although debate continues around 
the exact magnitude, nature and generalizability of differences.  In 2002, Baron Cohen 
hypothesized that ASD may in fact be an extreme manifestation of the male brain (Baron-
Cohen, 2002).    
Androgens, such as testosterone, have an established role in fetal brain 
development and differentiation leading to sexual dimorphism (Kimura, Okanoya, & 
Wada, 1999; Peper & Koolschijn, 2012).  The predominant source of fetal exposure to 
androgens in-utero are through endogenous production by the fetal gonads and adrenal 
glands (Baron-Cohen, Lutchmaya, & Knickmeyer, 2004; Blackburn, 2007). Only low 
  
 
amounts of exogenous testosterone passively diffuse across the placenta from maternal 
circulation under normal circumstances (Atkinson, Campbell, Cawood, & Oakey, 1996; 
Sun et al., 2012). Elevated prenatal testosterone levels are associated with sex differences 
in play behavior (van de Beek, van Goozen, Buitelaar, & Cohen-Kettenis, 2009), spatial 
abilities (Chapman et al., 2006) and language difficulties (Whitehouse, Mattes, Maybery, 
Sawyer, et al., 2012). In addition, defeminization of sex-typical play has been observed 
among girls diagnosed with ASD (Chapman et al., 2006).  
It is increasingly recognized that there may be multiple periods when the 
developing brain is susceptible to the influence of testosterone (Cohen-Bendahan, van de 
Beek, & Berenbaum, 2005; Zambrano, Guzman, Rodriguez-Gonzalez, Durand-Carbajal, 
& Nathanielsz, 2014). Fetal androgen production is based on the cooperative efforts of 
several endocrine organs.  Fetal gonads and adrenal glands are the predominant sources 
of androgen precursors, which themselves have low androgenic activity.  The androgen 
precursors are then converted to androgens by the placenta (Baron-Cohen et al., 2004; 
Blackburn, 2007; Dawson, 2013; Kallen, 2004; Paskova et al., 2014) and transferred back 
into fetal circulation.  There is a minimal amount of maternal contribution of androgens 
to fetal circulating androgens as the placenta rapidly metabolizes and inactivates 
maternally derived hormones (Atkinson et al., 1996; Sun et al., 2012).  
Several previous studies have focused on using amniotic fluid to determine fetal 
testosterone levels. However, due to inherent risks of amniocentesis, samples are limited 
to those with clinical indications for this invasive procedure. In comparison, umbilical 
cord blood is easily collected.  (Kimura et al., 1999; Peper & Koolschijn, 2012; Swaab, 
  
 
Fliers, & Partiman, 1985).  Testosterone levels measured in cord blood would reflect fetal 
levels in late gestation when they are below their peak. Although a critical period for 
testosterone‟s influence on brain development has been assumed to coincide with the 
timing of the male-specific surge, studies in nonhuman primates (Goy, Bercovitch, & 
McBrair, 1988) show that levels of fetal testosterone later in pregnancy still 
independently influence sex-associated behaviors, while research in sheep (Roselli, Estill, 
Stadelman, Meaker, & Stormshak, 2011) has identified late pregnancy windows where 
fetal testosterone influences structural and organizational changes in the brain (Zambrano 
et al., 2014).     
Epidemiologic studies in humans measuring cord blood testosterone concentration 
have reported associations with spatial ability (Jacklin, Wilcox, & Maccoby, 1988) and 
language development (Whitehouse, Mattes, Maybery, Sawyer, et al., 2012). The only 
published study of cord blood testosterone level and ASD-related traits reported no 
relationship (Whitehouse, Mattes, Maybery, Dissanayake, et al., 2012).  However, the 
ASD trait assessment was performed when cohort members were 20 years of age and 
thus there had been decades of postnatal environmental and developmental influences on 
behavior in participants and differential loss-to-follow-up is likely among more affected 
individuals.    Furthermore, participants were drawn from the general population, so the 
expected prevalence of those with more extreme ASD-related traits would be very low.  
This study aims to investigate the association between umbilical cord blood testosterone 
level and autistic traits in a high risk cohort.  
  
  
 
Methods 
The Early Autism Risk Longitudinal Investigation (EARLI) is a high autism risk 
cohort following pregnant mothers with older child diagnosed with ASD (autistic 
disorder, Asperger syndrome or pervasive developmental disorder not otherwise 
specified).  EARLI families were recruited at four sites (Drexel/CHOP; Johns 
Hopkins/KKI; UC Davis; and Northern CA Kaiser) in three distinct US regions 
(Southeast Pennsylvania, Northeast Maryland, Northern California).   In addition to 
having a biological child with an ASD confirmed by EARLI study clinicians, to be 
eligible mothers also had to communicate in English or Spanish and, at recruitment, meet 
the following criteria: be 18 years or older; live within 2 hours of a study site; and be less 
than 29 weeks pregnant. The design of the EARLI study is described in more detail in 
Newschaffer et al. (Newschaffer et al., 2012).  Mothers were provided with delivery 
sampling kits for cord blood collection prior to delivery. EARLI made arrangements with 
obstetricians/midwives and birth hospital labor and delivery staff to assure proper sample 
collection and temporary storage.  The EARLI protocol instructs trained nurses that blood 
should be collected from the umbilical vein; however, it is likely that arterial cord blood 
is also collected.   The development of children born into the cohort is closely followed 
through age three.  This study considered 212 subjects born into EARLI who reached one 
year of age by January 31, 2015.   Of 212 subjects, 37 subjects were excluded because 
they were either missing umbilical cord blood samples or 12 month developmental 
assessment. Demographic characteristics were similar between subjects included and 
excluded from the study (Appendix Table 1).   
  
 
Testosterone (T), androstenedione (A4) and dehyroepiandrosterone (DHEA) and 
internal standards 
2
H3-testosterone (
2
H3-T) and 19-
2
H3-androstenedione (
2
H3-A4) were 
extracted from cord blood using liquid-liquid extraction. T, A4, DHEA, 
2
H3-T and 
2
H3-
A4 were measured using a liquid chromatography-tandem mass spectrometry (LC-
MS/MS) assay and a calibration curve linear across the range of the samples as 
previously described (CPR Pharma Services Pty Ltd, Thebarton, SA) (Keelan et al., 
2012).  Limit of quantification (LOQ) was specified as a minimum signal-to-noise ratio 
of at least 5:1, with quality controls at the LOQ successfully quantified within 20% of its 
nominal concentration.  Samples with below LOQ were assigned new values 
(LOQ/square root of 2: T=0.12, A4=0.25, DHEA=2.45 ) (Hornung, 1990). 
The principal outcome variable was ASD-related phenotype assessed using  the 
AOSI, a semi-structured direct observational measure using visual tracking and attention 
disengagement, coordination of eye gaze and action, imitation, affective responses, early 
social-communicative behaviors, behavioral reactivity, and sensory motor development, 
administered at age one (Bryson, Zwaigenbaum, McDermott, Rombough, & Brian, 
2008). These 16 items are  rated on three to four point scales then summed to generate a 
total score and takes approximately 20 minutes to complete (Bryson et al., 2008).  EARLI 
study clinicians engaged in regular exercises to maintain cross-site reliability.  Total 
AOSI score has predicted subsequent ASD diagnosis in other high risk sibling cohort 
studies (Bryson et al., 2008; Zwaigenbaum et al., 2005; Zwaigenbaum, Estes, & Gu, 
2012).  
  
 
 Covariates of interest include sex, maternal age, sex of older sibling with ASD 
(proband) and gestational age, all of which have been associated with fetal androgen level 
and ASD risk (Appendix Table 2).  Wilcoxon rank-sum tests were used to test for 
differences between non-normally distributed continuous variables and t-test for normally 
distributed continuous variables. A χ2 test was used to test for difference between 
categorical variables.   
Linear regression was used to estimate the association between androgen levels 
and AOSI cores. Total AOSI scores were positively skewed and log transformed. 
AOSI+1 values were used to account for subjects with zero AOSI score (Appendix 
Figure 1). In these models, we examined unadjusted and adjusted associations between 
ln(AOSI+1) and ln(hormone concentration).  To explore whether any association 
between androgen levels and AOSI scores differed across groups defined by either the 
subject, or the subject‟s older affected sibling‟s sex, separate models were fit in these 
subgroups and models also fit in the full data incorporating interaction terms.  Cook‟s D 
was used to identify influential observations in regression models with 0.02 (4/n) was 
used as cut off. 
An additional analysis was also conducted in a subgroup of 82 subjects with 
available 36 month follow-up data.   Cord blood androgen levels were compared across 
three outcome categories,  ASD, other non-typically developing (non-TD), and typically 
developing (TD), based on criteria integrating  clinician judgement and results from the 
Autism Diagnostic Observation Schedule and Mullen Scales of Early Learning 
  
 
standardized observational assessment data (Ozonoff et al., 2014). All analyses were 
performed using STATA 12 (StataCorp., 2011.).  
Results 
Overall and sex-stratified characteristics of the study sample (95 males, 80 
females) are shown in Table 1. There are no observed sex differences in maternal age, 
gestational age at delivery, total number of pregnancy, cesarean section, education, race, 
ethnicity, and older ASD sibling sex.  Among the 175 cord blood samples analyzed, T, 
A4 and DHEA measured below the limits of quantification (0.17 nmol/L, 0.35 nmol/L 
and 3.47 nmol/L, respectively) in 10, 1 and 12 percent of the samples, respectively (Table 
2).    Females had a greater proportion of T measuring below LOQ and males had higher 
proportion of DHEA measuring below LOQ (Table 2).  Distributions of T, A4, and 
DHEA were all positively skewed (Appendix Figure 1) and natural log transformed 
values were used for the analysis.  Median values for T, A4, and DHEA were (0.44 
nmol/L, 1.74 nmol/L, and 6.93 nmol/L, respectively) (Table 2).  All three androgens (T, 
A4, and DHEA) were positively correlated with each other, with the highest observed 
pearson correlations in females being 0.49 between log-T and log-A4 and 0.64 between 
log-T and log-DHEA and the highest observed correlation in males being 0.56 between 
log-A4 and log-DHEA (Appendix Table 3).  Sex differences among androgens were 
assessed using the Wilcoxon rank sum test.  Levels of T were on average higher 
(P<0.0001) in males (geometric mean=0.6 nmol/L; GSD=1.8) verses females (geometric 
mean=0.3 nmol/L; SD=1.8) (Table 2). Levels of A4 were also higher in males.   Levels 
of DHEA were on average higher (P=0.002) in females (geometric mean=8.4 nmol/L; 
GSD=1.9) compared to males (geometric mean=6.5 nmol/L; GSD=2.0) (Table 2).  
  
 
Males had a slightly higher geometric mean AOSI score of 5.1 (SD 2.2) compared 
to females (geometric mean=4.6; SD= 2.1) though the difference was not statistically 
significant using the Wilcoxon rank sum test (P=0.39) (Figure 1).  Total AOSI scores 
were positively skewed and loge transformed (AOSI+1) values were used to account for 
subjects with zero scores (Appendix C). Pearson correlations of androgens (T, A4 and 
DHEA) with AOSI were weak (r=0.14, 0.06, and 0.06, respectively) (Appendix Table 3).   
Figure 2 shows a scatterplot of male (circle) and female (triangle) cord blood T 
levels against AOSI score.   Scatter plots of cord blood A4 and DHEA against AOSI 
score can be found in Appendix Figure 2. An unadjusted linear regression model fit after 
removing one subject with a T level more than three standard deviation away from the 
mean (Cook‟s D = 0.02 (4/n), suggested a positive association (regression coefficient 
0.16, 95% CI -0.01, 0.33; p=0.06).  The average increase in AOSI score associated with 
an increase from the first to fourth quartile median T values was 1.14 points (Table 3). 
This effect size did not change substantively after adjusting for gestational age and 
mother‟s age (Table 4) or A4 and DHEA (Appendix Table 7). Cesarean delivery was not 
associated with cord androgen level or AOSI score in our sample and therefore was not 
included in the adjusted model (Appendix Table 2).  Stratifying by sex revealed little 
differences in the association between testosterone and total AOSI score and the test of 
heterogeneity supported lack of heterogeneity (P=0.98) (Table 4). Unadjusted analyses of 
A4 and DHEA showed smaller average associations with AOSI score (Table 3) and 
findings were also not influenced by adjustment nor did they vary by subject sex 
(Appendix Table 5).    
  
 
After stratification by sex of the older sibling previously diagnosed with ASD 
(proband), there were indications that the association between T and AOSI score was 
markedly stronger in those with an affected female older sibling (Figure 3).  The 
magnitude of the estimated adjusted association between log-testosterone and log-AOSI 
score was six times greater in subjects with female affected probands compared those 
with male affected probands and the statistical test for interaction was significant 
(P=0.02) (Table 6). In those with female proband the average AOSI score difference of  
5.7 was associated with an increase from the first to fourth quartile median T values 
while there was no difference in those with male proband (Table 6). No heterogeneity of 
effect in other androgens by proband sex was observed in separate regression models 
with interaction terms (Appendix Table 6).  Comparison of geometric mean cord blood 
testosterone levels across sibling sex within proband sex strata indicated that testosterone 
was higher in male subjects regardless of proband sex (t-test; male proband P=<0.0001, 
female proband P=0.003). Geometric mean AOSI score showed no sex difference among 
subjects with male proband (P=0.98), while males AOSI score was greater among 
subjects with female proband (P=0.1) (Table 5). 
Additional analyses were conducted in the subgroup (n=82) of subjects with 
available 36 month data suggested that testosterone was higher in subjects meeting 
criteria for ASD  compared to those not meeting criteria (ANOVA; P=0.02) (Figure 4). 
Stratifying this subgroup by sex of the older affected proband suggested a similar pattern 
as that seen with 12 month AOSI scores, where the highest cord testosterone was 
observed in affected subjects with female older siblings. However, samples were small, 
especially for those with female siblings (Table 7).   
  
 
Discussion  
This study was the first investigation of the association between prenatal 
androgen exposure and early autism-related phenotype among infant siblings of older 
children previously diagnosed with ASD.  We found overall that elevated umbilical cord 
testosterone level was associated with a weak increase in 12 month AOSI score. This 
finding is generally consistent with previous reports by Auyeung et al that used amniotic 
fluid samples in populations unselected on ASD family history, but who were selected on 
clinical indications of amniocentesis (Auyeung et al., 2012; Auyeung et al., 2009; 
Auyeung, Taylor, Hackett, & Baron-Cohen, 2010). In addition, our findings also suggest 
that the weak overall association is driven by a stronger association among subjects with 
female probands.  This implies that distinct etiologic mechanisms may be involved in 
multiplex families with female affected children.  The observed heterogeneity of effect 
by proband sex persisted in analyses limited to those with available 36 month ASD 
outcome data supporting the notion that the observed effect is not an artifact of early 
phenotypic evaluation. 
Most of the available data on the influence of proband sex on ASD etiology in 
multiplex families comes from recurrence risk studies.   A recent large registry study in 
Sweden found the recurrence risk ratio (defined as the recurrence risk in those with 
affected siblings compared to the recurrence risk in those without siblings) was 
approximately 20% greater when the already affected sibling was female; however, that 
this difference was not statistically significant (Sandin et al., 2014).  In a large case-
control study of 29,384 siblings with older ASD-affected probands, ASD odds were also 
modestly higher in those with female probands (OR=1.18 [0.95-1.45]), although, again, 
  
 
this difference was not statistical significant (Risch et al., 2014).   A prospective cohort 
study of infant siblings (n=448) of ASD probands observed overall recurrence risk of 
27% that did not differ by proband gender (male proband: 27%, female proband: 26%) 
(Zwaigenbaum, Bryson, et al., 2012).  Similarly, the Baby Siblings Research Consortium 
(n=664), which pools data from multiple high risk infant sibling cohort studies, reported 
sibling recurrence risk of 18% with no statistically significant difference (P=0.2) by 
proband sex (stratified point estimates of recurrence were not provided) (Ozonoff et al., 
2011).  Our study is comparable in design to the latter two studies, except our outcome 
was early ASD-related phenotype as measured by AOSI, as opposed to 36 month 
outcome classification.  Geometric mean AOSI scores in siblings with male and female 
probands were 3.8 (GSD=2.6) and 4.3 (GSD=2.1), respectively.  At the time of these 
analyses, ASD diagnoses were only available for 82 subjects, and reflecting the general 
sex distribution of ASD, only 14 of these had female affected probands.   Of these, 3 
(21.4%) had ASD while 9 of the 68 (13.2%) subjects with male affected probands had 
ASD.  This difference is not statistically significant but, at this sample size, there is 
limited power to detect modest differences in recurrence risk.  
While the available evidence does not support ASD sibling recurrence risk 
difference by proband sex, heterogeneity in underlying etiologic mechanisms across 
families with and without female affected members is still possible.   Most likely, this 
heterogeneity would be driven by differences in genetic liability across these family 
types.  The multi-factorial multi-threshold model of ASD suggests that female sex is 
generally protective against ASD and therefore affected females are more likely to have 
increased etiological/genetic load (Lai, Lombardo, Auyeung, Chakrabarti, & Baron-
  
 
Cohen, 2015).  Consequently, multiplex families with affected females may also have 
increased enrichment, compared to families with affected males, for a variety of ASD-
related genetic variants.   
Our work suggests that one mechanism differentially operating in families with 
affected females might involve prenatal testosterone and, indeed, it is plausible that 
genetic liability may play a role in this mechanism.  To date, there have been more than 
ten genes associated with both autism or autism-related phenotype that are also associated 
with some aspect of sex steroid function (i.e., synthesis (Chakrabarti et al., 2009), 
transport (Chakrabarti et al., 2009), metabolism (Chakrabarti et al., 2009), or feedback 
mechanism.(Sarachana & Hu, 2013)).   Genetic variants might also modulate the 
susceptibility of the developing brain to endogenous testosterone.   For example, there are 
two known androgen receptor polymorphisms and, for one, repeat sequence length has 
been inversely associated receptor transcription activity (Beilin, Ball, Favaloro, & Zajac, 
2000; Henningsson et al., 2009).   These polymorphisms are located on the X 
chromosome (Zhou, Wong, Sar, & Wilson, 1994) and there has been one small 
investigation showing the variants linked to higher transcription activity to be associated 
with ASD in female cases only. 
One limitation of this study is that it is comprised of multiplex families with at 
least one child diagnosed with ASD and may not be generalizable to the general 
population. Generalizability of increase in testosterone dependent ASD risk observed 
among siblings of female proband would be limited to multiplex families.  Another 
concern is that while cord blood samples were supposed to be venous blood, collection, 
  
 
which was often done by delivery room personnel as opposed to study staff, most likely 
resulted in mix of arterial and venous blood. While androgens in the umbilical artery (UA) 
primarily reflect circulating fetal androgens from fetal adrenal and gonad, those in the 
umbilical vein (UV) also reflect androgen activity in placenta (Blackburn, 2007).  A 
recent study comparing UA and UV androgen levels found that while there are 
differences between UA and UV androgen levels, these are highly correlated 
(r=0.67~0.83) (Paskova et al., 2014).  Finally, our findings were based on early 
evaluation of ASD-related phenotype at one-year of age. Generally, ASD assessment at 
age three or later has been standard in autism research. However, evidence has been 
accumulating in the stability of ASD classification made at earlier ages (Sagiv, 
Kalkbrenner, & Bellinger, 2015) and a recent study found significant correlation between 
14 months AOSI and 36 month ADOS score (r=0.4, P=0.005) (Gammer et al., 2015).  
Our findings suggest that increase in prenatal testosterone levels are related to autistic 
traits and this mechanism might be more important in families with female ASD in the 
pedigree.  
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TABLES  
 
Table 1. Characteristics of the study cohort by sex. 
 
Total 
(n=175) 
 
Female 
(n=80) 
 
Male 
(n=95) 
 Characteristics Mean SD 
 
Mean SD 
 
Mean SD P-val 
Maternal age 33.8 4.5   33.4 4.0   34.1 4.8 0.31 
Gestational age at delivery 39.4 1.6 
 
39.5 1.4 
 
39.3 1.7 0.35 
Total number of pregnancies 3.7 1.5 
 
3.6 1.4 
 
3.8 1.5 0.38 
Total AOSI score 5.26 4.27 
 
4.81 3.76 
 
5.63 4.64 0.45 
 
% n 
 
% n 
 
% n 
 Cesarean Section 42.1 121 
 
43.4 53 
 
41.1 68 0.81 
Education 
 
175 
  
80 
  
95 0.33 
<9th 2.9 
  
5.0 
  
1.1 
  High school graduation 8.1 
  
10.0 
  
6.4 
  College degree 64.4 
  
62.5 
  
66.0 
  Graduate/ Professional degree 24.7 
  
22.5 
  
26.6 
  Race  
 
175 
  
80 
  
95 0.54 
Asian 11.2 
  
11.4 
  
11.1 
  Black  9.5 
  
13.9 
  
5.6 
  Other 8.3 
  
18.6 
  
10.0 
  White  64.5 
  
61.0 
  
66.7 
  Unknown  5.9 
  
7.6 
  
4.4 
  Hispanic/Latino 17.5 168 
 
15.1 79 
 
19.5 90 0.46 
Male Proband  85.1 175    84.2  80   86.3  95 0.71 
 
  
 
Table 2. Testosterone (T), androstenedione (A4), dehydroepiandrostenedione (DHEA) 
levels (nmol/L) in umbilical cord samples. 
 
Androgen N<LOQ GM GSD IQR 
Total  
(n=175) 
T 19 0.43 1.94 0.33-0.44 
A4 2 1.81 1.59 1.42-1.75 
DHEA 21 6.93 1.98 4.78-6.64 
Female* 
(n=80) 
T 16 0.30 1.75 0.2-0.34 
A4 1 1.70 1.51 1.35-1.73 
DHEA 6 8.42 1.90 5.94-8.42 
Male 
(n=95) 
T 3 0.58 1.79 0.4-0.62 
A4 1 1.92 1.64 1.48-1.75 
DHEA 15 6.46 2.01 4.23-6.15 
*Test of sex difference of GM using t-test. T: P<0.0001, A4: P=0.26, and DHEA: P=0.002; 
LOQ=limit of quantification; GM= geometric mean; GSD=geometric standard deviation; 
IQR=inter-quartile range 
 
 
 
  
  
 
Table 3. Unadjusted regression models of loge transformed testosterone (T), 
androstenedione (A4), dehydroepiandrostenedione (DHEA) levels and total loge 
(AOSI+1) scores (n=175).  
Androgen  
Estimated 
regression  
coefficient 95% CI P-val 
Predicted AOSI change 
between 1st  and 4th quartile 
median testosterone 
T 0.16 -0.01 0.33 0.06 1.14 
A4 0.10 -0.14 0.34 0.42 0.52 
DHEA 0.07 -0.10 0.23 0.43 0.66 
  
 
 
 
Table 4. Adjusted* and sex stratified regression models of loge transformed testosterone 
(T) level and total loge (AOSI+1) scores. 
  n 
Estimated 
regression  
coefficient  
for ln(T) 95% CI 
P-
val 
Predicted AOSI change 
between 1st  and 4th 
quartile median 
testosterone 
Total  175 0.18 0.01 0.36 0.04 1.34 
Female 
80 
0.18 
-
0.11 0.47 0.23 1.31 
Male  
95 
0.23 
-
0.06 0.52 0.11 1.52 
Test of heterogeneity of effect by sex was not significant (P=0.98); *Adjusted for gestational age 
and maternal age without outlier. 
 
  
  
 
Table 5. Sibling‟s geometric mean (GM) testosterone (nmol/L) and AOSI score by 
proband and sibling sex.  
      T    AOSI 
 Proband 
Sex  Sibling sex n GM   GSD P val*  GM  GSD P val^ 
 
Male  
Male  80 0.57 1.8 <.0001 4.8 2.1 0.96 
Female  69 0.30 1.7   4.8 2.0   
Female  
Male  15 0.64 1.7 0.003  6.9 2.3 0.1 
Female  11 0.29 1.9   3.7 2.7   
*Test of ln(T) across sibling sex using t-test; ^Test of ln(AOSI+1) across sibling sex using t-test; 
GM= geometric mean; GSD=geometric standard deviation 
 
 
 
Table 6. Adjusted* and proband (older child with ASD) sex stratified regression models 
of loge transformed testosterone (T) level and total loge (AOSI+1) scores. 
Proband Sex 
Estimated 
regression  
coefficient 
for ln(T) 95% CI P-val 
 
Predicted AOSI 
change between 1
st
  
and 4
th
 quartile 
median testosterone 
Female (n=26) 0.61 0.10 1.11 5.71 0.02 
Male (n=149) 0.09 -0.09 0.27 0.66 0.34 
Test of heterogeneity of effect by proband sex was significant (P=0.02); *Adjusted for gestational 
age and maternal age without outlier. 
 
  
  
 
Table 7. Geometric mean testosterone (nmol/L) by ASD classification assessed at 36 
months (ASD, non-typical development (non-TD), or typical development (TD)) in 
subjects with available data (n=82) overall and in subgroups defined by proband (older 
child with ASD) sex. 
 
Geometric mean testosterone 
(nmol/L)   
 
ASD 
(n=12) 
Non-TD 
(n=38) 
TD 
(n=32) 
 
P-val* 
All subjects 0.61 0.35 0.46 0.02 
Female Proband 1.03 0.37 0.45 0.14 
 
(n=3) (n=5) (n=6) 
 Male Proband 0.51 0.35 0.46 0.13 
 
(n=9) (n=33) (n=26)   
*Test of  ln(T) across 36 month ASD classification using ANOVA.  
  
 
FIGURES 
 
Figure 1. Distribution of Autism Observational Scales in Infants (AOSI) total scores by 
sex (n=175, Female=80, Male=95).  
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Figure 2. Relationship between umbilical cord testosterone level and AOSI score 
(n=175). 
 
 
  
Correlation coefficient: 0.14 (P = 0.06)
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Figure 3. Scatter plot of the sibling‟s testosterone level and total AOSI score by proband 
(older child with ASD) sex (line fitted to unadjusted model. ln(AOSI+1)=ln(T) by 
proband sex) (n=175). 
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Figure 4. Box plot of cord blood testosterone and broad autism phenotype categories 
(ASD, DD, and TD) by proband sex. 
 
 
0
.5
1
1
.5
2
ASD DD TD ASD DD TD
Proband Female Proband Male
T
e
s
to
s
te
o
n
re
 l
e
v
e
l 
(n
m
o
l/
L
)
  
 
 
APPENDIX 
 
Table A1. Demographic characteristics comparison between subjects included and 
excluded from the study. 
  
Total 
included in 
the study 
n=175 
Currently 
enrolled 
live birth 
n=212 
Excluded due 
to Missing 
Cord or AOSI 
with 12 month 
visit 
n=37 
Excluded vs 
included in the 
study 
 
  
mea
n sd mean sd mean sd P val 
Maternal age 33.8 4.5 34.1 4.8 35.3 6.2 0.08 
gestational age at delivery 39.4 1.6 39.2 1.8 38.6 2.5 0.12 
total number of pregnancy 3.7 1.5 3.7 1.5 3.81 1.91 0.97 
Total AOSI score 5.26 4.27 
     Cesarean Section (%) 35.6 
 
34.0 
 
25.0 
 
0.34 
High school degree or higher (%) 95.5 
 
96.2 
 
94.5 
 
0.57 
Race (% White) 64.5 
 
61.1 
 
51.4 
 
0.18 
Ethnicity (%Hispanic/Latino) 17.5   17.3   13.9   0.55 
Sex (% Male)     54.6   55.0   0.96 
 
  
  
 
Table A2. Covariate univariate analysis with outcome (loge (AOSI+1) and exposure (loge 
T) of interest 
  
Log (AOSI+1) 
 
Log T 
 
  
beta P val 95% CI 
 
beta P val 95% CI 
Cesarean section*  0.13 0.36 -0.15 0.41  0.13 0.30 -0.12 0.38 
Gestational age at birth 
 
-0.04 0.28 -0.11 0.03 
 
-0.05 0.13 -0.11 0.01 
Sex (male=1) 
 
0.10 0.39 -0.13 0.32 
 
0.67 0.00 0.50 0.85 
Older ASD child sex (male=1) 
 
-0.094 0.56 -0.41 0.22 
 
-0.08 0.57 -0.36 0.2 
Mother's age   -0.01 0.69 -0.03 0.02 
 
0.02 0.10 
-
0.004 0.04 
*n=121 
           
 
 
  
  
 
Figure A1. Transformation Considerations 
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Figure A1. Transformation Considerations (continued) 
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Table A3. Extended pairwise Pearson‟s correlation 
    
log 
(AOSI+1) log T log A4 
log 
DHEA gestational age mother's age 
Total T 0.09 
     
 
A4 -0.02 
     
 
DHEA 0.04 
     
 
log T 0.14 1 
    
 
log A4 0.06 0.49** 1 
   
 
log DHEA 0.06 0.36** 0.49** 1 
  
 
gestational age -0.08 -0.12 -0.06 -0.12 1 
  mother's age -0.03 0.12 0.03 0.06 0.05 1 
Female log T 0.12 1 
    
 
log A4 -0.01 0.56** 1 
   
 
log DHEA 0.10 0.64** 0.48** 1 
  
 
gestational age -0.16 0.08 0.27* -0.05 1 
  mother's age 0.03 -0.04 -0.12 0.16 0.21 1 
Male log T 0.13 1 
    
 
log A4 0.10 0.45** 1 
   
 
log DHEA 0.06 0.46** 0.56** 1 
  
 
gestational age -0.03 -0.23* -0.24* -0.18 1 
  mother's age -0.08 0.18 0.09 0.03 -0.04 1 
*<0.05 **<0.001 
 
 
 
 
  
  
 
Figure A2. Scatter plot of log(AOSI+1) and testosterone level (ng/g), log 
androstenedione, and log DHEA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Table A4.  Bivariate analysis of loge (AOSI+1) and androgens.  
  Changes in androgen level 
Estimated 
regression  
coefficient 
Predicted 
change in 
AOSI 95% CI P val 
T 1 nmol/L increase 0.59 0.81 -0.39 1.58 0.24 
 Categorical*      
 
    0.12 to 0.3  0.13 0.14 -0.19 0.44 0.43 
 
    0.12 to 0.43  0.17 0.19 -0.15 0.49 0.29 
 
    0.12 to 0.66 0.23 0.26 -0.09 0.55 0.16 
A4 1 nmol/L increase -0.03 -0.03 -0.26 0.20 0.78 
 Categorical*      
 
    0.24 to 1.42 -0.03 -0.03 -0.34 0.29 0.87 
 
    0.24 to 1.74 0.12 0.13 -0.19 0.44 0.45 
     0.24 to 2.28 0.09 0.09 -0.23 0.41 0.59 
DHEA 1 nmol/L increase 0.01 0.01 -0.03 0.05 0.60 
 Categorical*      
 
    2.46 to 4.78  0.05 0.05 -0.27 0.37 0.75 
 
    2.46 to 6.93 0.14 0.15 -0.18 0.46 0.38 
     2.46 to 10.71 0.20 0.22 -0.12 0.52 0.21 
*based on quartile cutpoints 
 
 
 
  
  
 
Table A5. Sex stratified and interaction models for loge (AOSI+1) scores and 
androstenedione (A4) and dehydroepiandrosterone (DHEA) adjusted for maternal age 
and gestational age. 
  Androgen 
Estimated 
regression 
coefficient 
95% CI P val 
Multivariate* ln(A4) 0.09 -0.15 0.34 0.46 
  ln(DHEA) 0.06 -0.11 0.22 0.49 
Female* ln(A4) 0.08 -0.34 0.50 0.72 
 
ln(DHEA) 0.10 -0.16 0.36 0.46 
Male*  ln(A4) 0.16 -0.17 0.49 0.33 
  ln(DHEA) 0.06 -0.17 0.29 0.61 
 
 
 
Table A6.  Proband (older child with ASD) sex stratified and interaction models for loge 
(AOSI+1) scores and androstenedione (A4) and dehydroepiandrosterone (DHEA). 
  
Estimated 
regression  
coefficient 95% CI P val 
ln(A4) 0.45 -0.63 1.54 0.41 
Proband sex -0.37 -1.22 0.49 0.40 
Interaction term -0.37 -1.48 0.74 0.51 
ln(DHEA) 0.16 -0.22 0.54 0.39 
Proband sex -0.03 -0.45 0.39 0.90 
Interaction term -0.12 -0.54 0.30 0.58 
 
  
 
Table A7. Adjusted regression model of loge transformed testosterone (T), 
androstenedione (A4), dehydroepiandrostenedione (DHEA) levels and total loge 
(AOSI+1) scores (n=175).  
Androgens  
Estimated 
regression  
coefficient 95% CI P val 
T 0.16 -0.03 0.36 0.1 
A4 -0.03 -0.33 0.27 0.86 
DHEA 0.02 -0.17 0.21 0.85 
  
 
 
 
  
  
 
Table A8. Adjusted and stratified regression models for loge (AOSI+1) scores (including 
the outlier) 
    beta P val 95% CI 
Total  log T 0.16 0.07 -0.01 0.33 
n=175 gestational age -0.03 0.40 -0.10 0.04 
  Mom's age -0.01 0.56 -0.03 0.02 
Female log T 0.18 0.23 -0.11 0.47 
n=80 gestational age -0.10 0.12 -0.22 0.02 
 
Mom's age 0.01 0.54 -0.03 0.05 
Male log T 0.20 0.16 -0.08 0.48 
n=95 gestational age -0.0001 1.00 -0.09 0.09 
 
Mom's age -0.02 0.31 -0.05 0.02 
GEE log T 0.16 0.07 -0.01 0.33 
2 twin pairs gestational age -0.03 0.39 -0.10 0.04 
n=173 Mom's age -0.01 0.56 -0.03 0.02 
 
  
  
 
Table A9. Sibling‟s median testosterone level and AOSI score by proband sex  
      T    AOSI Sibling sex  
ttest 
(P val)     n GM  GM SD   GM  GM SD 
Exposed to  
Proband 
Male 
Male Sibling 80 0.6 1.8   4.8 2.1 0.96 
Female Sibling 69 0.3 1.7   4.8 2.0   
Exposed to 
Proband 
Female 
Male Sibling 15 0.6 1.7   6.9 2.3 0.1 
Female Sibling 11 0.3 1.9   3.7 2.7   
 
  
  
 
CHAPTER 4. STUDY III: Triclosan or Triclocarban Exposure and ASD-Related 
Phenotypes at 12 Months 
  
 
Abstract 
Background:  The antimicrobial agents triclosan (TCS) and triclocarban (TCC) have 
androgen disrupting potential and are widely used in household and personal care 
products. Increase in prenatal testosterone levels have been associated with increased 
autistic traits. However, the roles of prenatal TCS and TCC exposures in this context 
have not been explored. 
Study Design:  The EARLI (Early Autism Risk Longitudinal Investigation) cohort 
follows mothers of a child with autism spectrum disorders (ASD) at the start of a 
subsequent pregnancy. Surveys from 170 mothers gathered information used to estimate 
prenatal and postpartum TCS or TCC exposure. Linear regressions were used to 
determine association between these exposures and a measure of ASD phenotype in 
offspring assessed at 12 months.  
Results: ASD phenotype did not differ by TCS or TCC exposure and the results did not 
differ by sex of the child.  
Conclusion: These findings suggest that 12 month autistic traits are unrelated to either 
prenatal or postpartum TCS or TCC containing product use.  
 
Introduction 
 
Antimicrobial substances generally refer to products that kill microorganisms or 
prevent their proliferation. Microbicides began being incorporated into personal care 
products in the US during the 1970s and their use has risen dramatically (Schweizer, 
2001). They are now widely used in liquid soap, toothpaste, mouth rinse, cosmetics, 
plastics, textiles and other personal care products (Ahn et al., 2008; Calafat, Ye, Wong, 
Reidy, & Needham, 2008).  Triclosan (TCS) and triclocarban (TCC) are typical 
ingredients incorporated into antimicrobial personal care products. Widespread human 
exposure to TCS has been documented in National Health and Nutrition Examination 
Survey (NHANES), with 75% of US population between 2003 and 2004 testing positive 
(Calafat et al., 2008). TCS and TCC are readily absorbed through skin and eliminated 
  
 
rapidly from the body, with half-life of less than 24 hours (Dann & Hontela, 2011).  
Studies have detected TCS in human urine, blood serum, amniotic fluid and even breast 
milk (Dann & Hontela, 2011; Philippat et al., 2013). At the same time, several studies 
have shown that TCS containing products were no more effective than regular soap and 
can potentially encourage the growth of drug-resistant bacteria (Aiello AE, 2007).   
 Endocrine disrupting characteristics of TCS and TCC have been identified in 
both in vivo and in vitro studies (Witorsch & Thomas, 2010).  TCS has been shown to 
have androgen enhancing properties in aquatic species (Foran, Bennett, & Benson, 2000; 
Ishibashi et al., 2004), and rodents (National Industrial Chemicals & Assessment, 2009).  
Two in vitro studies using human breast cancer cell lines found TCS enhanced 
androgenic activity through nuclear androgen receptor activation (Christen, Crettaz, 
Oberli-Schrammli, & Fent, 2010; Gee, Charles, Taylor, & Darbre, 2008). A few in vitro 
analyses, found that while TCC itself had no androgenic properties (Ahn et al., 2008; 
Christen et al., 2010), it amplified the signaling activity of testosterone (Ahn et al., 2008).  
In addition, one study reported that TCC does not compete with androgens for androgen 
receptor binding (Chen et al., 2008). The exact mechanisms for the potential androgenic 
activity of TCS and TCC are still unknown.  
Androgens, such as testosterone, have an established role in fetal brain 
development and sex differentiation (Kimura, Okanoya, & Wada, 1999; Peper & 
Koolschijn, 2012; Swaab, Fliers, & Partiman, 1985).  Sex specific behaviors are driven 
by sex hormone dependent brain differentiation during sensitive prenatal windows.  
Elevated prenatal testosterone levels have been associated with sex differences in play 
  
 
behavior (Meaney & McEwen, 1986; van de Beek, van Goozen, Buitelaar, & Cohen-
Kettenis, 2009), spatial abilities (Chapman et al., 2006; Knickmeyer, Baron-Cohen, 
Raggatt, & Taylor, 2005), social difficulties (Knickmeyer et al., 2005), decreased 
empathy (Chapman et al., 2006), and language difficulties (Whitehouse et al., 2012). 
Moreover, de-feminization of sex-typical play has been observed among girls diagnosed 
with autism spectrum disorders (ASD) (Chapman et al., 2006). Impaired social 
interaction and communication are core characteristics associated with ASD and Baron 
Cohen (2002) has hypothesized that ASD may in fact be an extreme manifestation of the 
“male brain” (Baron-Cohen, 2002).  Elevated prenatal testosterone level has been 
associated with autistic traits in several studies (Auyeung et al., 2012; Auyeung et al., 
2009; Auyeung, Lombardo, & Baron-Cohen, 2013).  However no epidemiologic study 
has investigated association between prenatal TCS or TCC exposure and ASD risk. 
Methods 
 
Study population 
The Early Autism Risk Longitudinal Investigation (EARLI) is a high autism risk 
cohort following pregnant mothers with older child diagnosed with ASD (autistic 
disorder, Asperger syndrome or pervasive developmental disorder not otherwise 
specified).  EARLI families were recruited at four EARLI Network sites (Drexel/CHOP; 
Johns Hopkins/KKI; UC Davis; and Northern CA Kaiser) in three distinct US regions 
(Southeast Pennsylvania, Northeast Maryland, Northern California).   In addition to 
having a biological child with an ASD confirmed by EARLI study clinicians, to be 
eligible mothers also had to communicate in English or Spanish and, at recruitment, meet 
  
 
the following criteria: be 18 years or older; live within 2 hours of a study site; and be less 
than 29 weeks pregnant. This report considered 212 subjects born into EARLI and 
followed to one year of age by January 31, 2015.   The means of evaluating outcome at 
this age, discussed further below, is a standardized direct observation assessment for 
autism-related phenotype, the Autism Observational Scales in Infants (AOSI).  Of 212 
subjects, 42 subjects were excluded because they were either missing an exposure 
questionnaire or an AOSI total score.  The design of the EARLI study is described in 
more detail in Newschaffer et al. (Newschaffer et al., 2012).   
Exposure to triclosan and triclocarban 
Maternal interview were administered during second trimester prenatal and 
postpartum home visits.  The interview included questions on soaps (dish, hand, body and 
facial) and toothpastes use. The mothers were asked to report use of these products „since 
3 months before you became pregnant until now‟ and subsequently asked to name up to 
three products by categories (Methods appendix 5). The median gestational age of these 
interviews were 39.4 weeks (inter-quartile range (IQR) = 39, 40.2).   In analyses here, 
personal care product use reported during this interview is referred to as the “early 
prenatal exposure.” During the postpartum home visit, mothers were asked similar 
questions on personal care products used since the first home visit (Methods appendix 5).  
Exposure from products reported during the second interview is referred to here as “late 
prenatal/early postpartum exposure.” For each exposure widow, dichotomous TCS/TCC 
exposure was defined as any use of the TCS/TCC containing products from any 
categories. Maximum of three products could be reported per subject in each personal 
  
 
care product category. Additionally, total TCS/TCC products were defined as sum of all 
the reported TCS/TCC containing products across categories (maximum of 12). 
Personal care products containing TCS or TCC were identified using data from 
National Institutes of Health „Household Product Database‟ website (NIH, 2014) and US 
Environmental Protection Agency „CPCat: Chemical and Product Categories‟ website 
(EPA, 2014).  A total of 127 such products were extracted from the two web sources in 
December 2014 (Methods appendix 4).  The product names of dish soap, hand soap, body 
soap, facial soap, and toothpaste were matched to the NIH and EPA product list to 
determine the mother's exposure to TCS/TCC during pregnancy.  We excluded subjects 
missing first and second interview data (2 and 28 subjects, respectively). In the analysis, 
168 subjects with early prenatal period TCS/TCC and 142 subjects with late 
prenatal/early postpartum period TCS/TCC product use information were included. 
Outcome measure 
The principal outcome variable was ASD-related phenotype assessed using  the 
AOSI, a semi-structured direct observational measure using visual tracking and attention 
disengagement, coordination of eye gaze and action, imitation, affective responses, early 
social-communicative behaviors, behavioral reactivity, and sensory motor development, 
administered at age one (Bryson, Zwaigenbaum, McDermott, Rombough, & Brian, 
2008). These 16 items are  rated on three to four point scales then summed to generate a 
total score and takes approximately 20 minutes to complete (Bryson et al., 2008).  EARLI 
study clinicians engaged in regular exercises to maintain cross-site reliability.  Total 
AOSI score has predicted subsequent ASD diagnosis in other high risk sibling cohort 
  
 
studies (Bryson et al., 2008; Zwaigenbaum et al., 2005; Zwaigenbaum, Estes, & Gu, 
2012).  Of 212 subjects, 42 subjects were excluded because they were either missing a 
home visit survey or an AOSI total score. 
Covariates 
Advanced maternal age has been associated with increased ASD risk (Lai, 
Lombardo, & Baron-Cohen, 2014) and TCS exposure (Arbuckle et al., 2015) and was the 
only potential confounder included in the analyses. Because androgenic properties of 
TCS/TCC may manifest differently in males and females, sex was considered as potential 
effect modifier. Female fetuses maintain low testosterone levels throughout gestation and 
males are exposed to early gestational testosterone surge. One of the androgenic 
properties of TCS is androgen receptor activation and this effect is likely of different 
magnitude in high versus low testosterone environments. Cord blood testosterone levels 
were also explored as potential effect modifiers in this study. Cord blood testosterone 
level was categorized into quartiles using sex specific cut points and the highest quartile 
was compared to the rest. 
Mothers were provided with delivery sampling kits for cord blood collection prior 
to delivery. EARLI made arrangements with obstetricians/midwives and birth hospital 
labor and delivery staff to assure proper sample collection and temporary storage.  The 
EARLI protocol instructs trained nurses that blood should be collected from the umbilical 
vein.   Testosterone (T) was measured using a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) assay and a calibration curve linear across the range of the 
  
 
samples as previously described (CPR Pharma Services Pty Ltd, Thebarton, SA) (Keelan 
et al., 2012).  
Statistical analysis 
Wilcoxon rank-sum tests were used to test for differences between non-normally 
distributed continuous variables and t-tests were used for normally distributed continuous 
variables. Chi-squared (χ2) tests were test was used to test for differences between 
categorical variables. Distributions of AOSI was positively skewed and natural log 
transformed (AOSI+1) values were used to account for subjects with zero AOSI score.   
Linear regression was used to examine whether adjustment for maternal age influenced 
the association between TCC/TCS use and ln(AOSI+1). Tests of heterogeneity of effect 
were conducted first by stratifying subjects by sex and cord blood testosterone levels 
(below and above 4
th
 quartile) in separate regression models. Then, using the full sample, 
models were fit with interaction terms to test whether the association between TCC/TCS 
and AOSI score differed across sex or testosterone levels. An additional analysis was also 
conducted in a subgroup of 82 subjects with available 36 month follow-up data.   Cord 
blood androgen levels were compared across three outcome categories,  ASD, other non-
typically developing (non-TD), and typically developing (TD), based on criteria 
integrating  clinician judgement and results from the Autism Diagnostic Observation 
Schedule and Mullen Scales of Early Learning standardized observational assessment 
data (Ozonoff et al., 2014). All analyses were performed using STATA 12 (StataCorp., 
2011.).  
Results 
  
 
More than 217 different products containing TCS/TCC were included in two 
public databases (EPA, 2014; NIH, 2014). Most of the TCS/TCC containing products 
identified in the public databases are for daily use, and might be used often multiple times 
throughout the day. Antibacterial liquid and bar soap was the product category with the 
most reports (36%) followed by deodorant/perfume (21%), body/face soaps (15%), dish 
soaps (8%) and toothpaste (4%) (Figure 1).  Other product categories containing 
TCC/TCS were reported, included lotion, cosmetic, shave gel, shampoo, homecare 
products and children‟s toys.   
During the early prenatal period, 89% of mothers reported using at least one 
personal care product potentially containing TCS/TCC. In the late prenatal/early 
postpartum period, 73% of mothers reported using personal care products potentially 
containing TCS/TCC. The demographic characteristics of the participants by TCS/TCC 
product use are described in Table 1. There are no observed differences in mother‟s age, 
gestational age, sex of child, education, race and ethnicity across TCC/TCS users and 
nonusers in either exposure period.  Among the four categories of personal care products 
examined, the largest proportion of mothers (67%) reported using TCC/TCS-containing 
dish soap, followed by antibacterial soap (49%), toothpaste (45%) and body/face soap 
(19%) during the early prenatal period (Table 2). The maximum number of antibacterial 
soaps reported was three whereas the maximum reported for dish soap, body/face soap 
and toothpaste was two.   
There was no statistically significant difference in AOSI score geometric means 
between TCS/TCC product users and non-users, overall and sex stratified, during the 
  
 
early prenatal period (Table 3). Similarly, no association was seen between late 
prenatal/early postpartum TCS/TCC product users (Table 4).   No association was found 
between category specific early prenatal or late prenatal/early postnatal TCS/TCC 
product use (dish soap, antibacterial soaps, body/face soaps, and toothpaste) and total 
ln(AOSI+1) scores (early prenatal period regression coefficient range:  -0.02 ~ 0.1 (P 
value range 0.4~0.9); late prenatal/early postpartum period regression coefficient range: -
0.05 ~ 0.1 (P value range 0.4~0.8) (Appendix Table 2).  The total number of TCS/TCC 
products used by each subject across all categories during the early prenatal period 
(ranging from 0-6), during the late prenatal/early postnatal (ranging from 0-5), and across 
both periods (ranging from 0-10) showed no correlation (Spearman‟s rho: early prenatal= 
0.07 (p=0.4); late prenatal/early postpartum=0.01 (p=0.9), overall=0.04 (p=0.6)) with 
total AOSI score (Appendix Figure 1-3).  
Stratifying by sex revealed small differences in the association between TCS/TCC 
product use and total AOSI score, but the test of heterogeneity was not statistically 
significant for early prenatal (P=0.16) or late prenatal/early postnatal (P=0.4) periods 
(Table 6). Association between TCS/TCC product use and total AOSI score showed little 
differences when stratified by cord blood testosterone categories and the test of 
heterogeneity was not statistically significant in early prenatal (overall (P=0.8), female 
(P=0.8), and male (P=0.3)) and late prenatal/early postnatal (overall (P=0.4), female 
(P=0.5), and male (P=0.8)) periods (Table 6). 
Additional analyses comparing early prenatal or late parental/early postpartum 
TCS/TCC product use in the subgroup (n=80) of subjects with available 36 month data 
  
 
did not differ across 36 month outcomes (ASD, developmental delay (DD), typical 
development (TD)) using χ2 test (P=0.4; 0.3, respectively) (Table 7). There was no 
association between 36 month ASD classification (compare to typical development) and 
early prenatal TCS/TCC product use compared to those who did not (P=0.4)  (Table 7). 
Discussion 
 
Findings from this investigation do not support an association between use of 
TCS or TCC-containing products during pregnancy and total AOSI scores. We found no 
correlation between the total number of TCS/TCC products and total AOSI score. The 
suggested lack of association persisted in analysis using 36 month ASD outcome 
classification, in a subset of subjects. These results could reflect a true absence of the 
association or could be a consequence of confounding, or measurement error. Further, a 
real association might have a modest effect size that was not detectable at this study size.  
With respect to confounding, serious prenatal infections have been associated 
with increased ASD risk (Lee et al., 2015). It is possible that mothers who experienced 
minor or major infection during pregnancy are more likely to use personal care products 
containing TCS/TCC. In contrast, mothers who use personal care products containing 
TCS/TCC might also be more likely to practice good hygiene in general. In this study, we 
did not adjust for prenatal infections. Previous studies have found association between 
high incomes (Calafat et al., 2008) and female sex (Koeppe, Ferguson, Colacino, & 
Meeker, 2013) with increased urinary TCS level. Another potential limitation is that our 
findings were based on early evaluation of ASD-related phenotype at one-year of age. 
Finally, our findings were based on early evaluation of ASD-related phenotype at one-
  
 
year of age. Generally, ASD assessment at age three or later has been standard in autism 
research. However, evidence has been accumulating in the stability of ASD classification 
made at earlier ages (Sagiv, Kalkbrenner, & Bellinger, 2015) and a recent study found 
significant correlation between 14 months AOSI and 36 month ADOS score (r=0.4, 
P=0.005) (Gammer et al., 2015).   
The interview based exposure assessment approach is vulnerable to measurement 
error.  The two TCS/TCC product databases used in this study are incomplete and capture 
only small subset of marketed TCS/TCC containing products in use.  Only a limited set 
of household products were collected and any exposure during work place or from 
sources outside of home is not captured.  The most likely source of non-residential 
exposure to TCS/TCC-containing products is TCS/TCC-containing liquid hand soaps 
because hand washing may be done outside of home. Quantifying exposure based only on 
product name is also a limitation because exact ingredient cannot be determined. Data 
entry error of product name and reliance on text matching also plays a role since 
TCS/TCC exposure is determined based on text entry of product name.  
TCS/TCC containing products are readily available over the counter and a high 
prevalence of TCS/TCC exposure was observed this study population consistent with 
past research. Since the number of unexposed subjects are small, this reduces overall 
statistical power to detect effects based on exposed versus unexposed comparison.  Lack 
of power observed in this study could be improved by increased recruitment of subjects 
and using continuous measure of TCS and TCC in biological samples such as serum and 
blood, which might also reduce measurement error. Although the current study grouped 
  
 
TCS and TCC exposure together, it is likely that TCS and TCC have different mechanism 
of action. Therefore, in future work TCS and TCC exposures should be examined 
separately. Determining TCS and TCC exposure separately using biosamples allows 
direct quantification of cross sectional TCS and TCC levels irrespective of sources.  
This initial investigation of TCS/TCC exposure to ASD-related phenotype did not 
support an association between early prenatal and late prenatal/early postpartum use of 
TCS or TCC-containing products and ASD.  However, more studies are needed using 
biomarkers which would better characterize the association between TCS/TCC exposure 
and ASD-related phenotype. Serum and urine concentration of TCS/TCC are both good 
alternative to questionnaire based measure. A recent study reported that TCS was 
detected better in urine compared to serum (Geens, Neels, & Covaci, 2009) due to fast 
excretion (half-life less than 24 hours) and ease of collection (Calafat et al., 2008; Koch 
et al., 2014; Sandborgh-Englund, Adolfsson-Erici, Odham, & Ekstrand, 2006; Scharpf, 
Hill, & Maibach, 1975).  Rapid elimination may result in high within-individual and 
between-individual variations (Koch et al., 2014).  A recent study monitored urine TCS 
variability in eight individuals for six days and observed high TCS intraclass correlation 
coefficient (ICC=0.93) and high within individual variability (Koch et al., 2014).  In 
future studies, a complete 24 hours urine collection could be used to quantify the TCS 
and TCC exposures.  
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TABLES 
 
Table 1. Demographic chracteristics of study population by any  triclosan- (TCS) or 
triclocarban -(TCC) containing product use during the early (early prenatal) and later 
(late prenatal/early postpartum) periods. 
  
Any early prenatal 
TCS/TCC product 
use     
Any late prenatal/ early 
postpartum TCS/TCC 
product use   
  
Yes 
(n=153) 
No 
(n=15) 
P-
val 
 
Yes  
(n=128) 
No  
(n=14) P-val 
        Mother's age (mean; sd) 34.3; 4.4 33.6; 5 0.6 
 
34; 4.4 35.5; 2.6 0.2 
Gestational age (mean; sd) 39.4; 1.6 
39.6; 
1.3 0.5 
 
39.3; 1.5 39.6; 1.2 0.4 
Sex of child (%male) 54.3 60 0.7 
 
54.7 64.3 0.5 
Education* 
  
0.6 
   
0.6 
  <9th 2.6 6.7 
  
3.2 7.1 
  High school graduation 6.54 13.3 
  
7.1 7.1 
  College degree 64.7 60 
  
66.1 50 
  Graduate/Professional 
degree 26.1 20 
  
23.6 35.7 
 Race (% White)** 66.9 73.3 0.6 
 
64.8 64.3 0.8 
Ethnicity (%Hispanic)^ 16.4 20 0.7  16.6 14.3 0.6 
Early prental:*no missing**n=160; 145; 15 ^n=161; 146; 15. Late prenatl/ early 
postpartum: *n=141;127;14 **n=133;119;14 ^n=137;123;14 
  
 
Table 2. Percent of subjects using triclosan- (TCS) or triclocarban- (TCC) containing 
products in each  personal care product category during the early (early prenatal) and 
later (late prenatal/early postpartum) periods. 
  
Early prenatal period  
(n=168)   
Late prenatal/ early  
postpartum period  
(n=142) 
  
Number of 
products* 
  
Number of 
products* 
Product categories Any use 1 2 3 
 
Any use 1 2 3 
Dish soap (%) 66.7 58.3 8.3 0 
 
71.9 61.7 10.2 0 
Antibacterial (%) 49.0 39.1 8.3 1.6 
 
55.5 44.5 9.4 1.6 
Body/face soap (%) 19.3 18.8 0.5 0 
 
17.2 16.4 0.8 0 
Toothpaste (%) 44.8 43.8 1.0 0   47.7 46.9 0.8 0 
*maxinum of 3 products were recorded per category 
 
 
 
  
  
 
Table 3. Total AOSI (Autism Observational Scales in Infants) scores by early prenatal 
triclosan (TCS)/ triclocarban (TCC) containing product use. 
  AOSI Total Score   
  
TCS/TCC 
product users 
 
Nonusers P-val^ 
 
IQR 
 
IQR 
 
       All * 2 to 7 
 
2 to 12 0.38 
Female**  2 to 7  
 
2 to 13 0.20 
Male***  2 to 8   2 to 11 0.96 
* n=170;153;15 **n=76;70;6 *** n=92;83;9. IQR: interquartile range. ^Ranksum test was used. 
 
 
 
Table 4. Total AOSI (Autism Observational Scales in Infants) scores by late 
prenatal/early postpartum- (TCS)/ triclocarban- (TCC) containing product use. 
  AOSI Total Score   
  
TCS/TCC 
product users 
 
Nonusers P-val^ 
 
IQR 
 
IQR 
 
       All * 2 to 7 
 
2 to 12 0.38 
Female**  2 to 7  
 
2 to 13 0.20 
Male***  2 to 8   2 to 11 0.96 
* n=142;128;14. **n=63;58;5. *** n=79;70;9.  IQR: interquartile range. ^Ranksum test was used. 
 
 
 
 
  
  
 
Table 5. Unadjusted and adjusted regression models of total loge (AOSI+1) scores and 
early (early prenatal) and later (late prenatal/early postpartum) TCS or TCC product use. 
  
Early prenatal period  
(n=168)   
Late prenatal/ early  
postpartum period  
(n=142) 
TCS/TCC 
product use 
estimated 
regression 
coefficient 95 % CI 
P-
val 
 
estimated 
regression 
coefficient 95 % CI 
P-
val 
Unadjusted -0.21 
-
0.61 0.20 0.3 
 
-0.11 
-
0.53 0.3 0.6 
Adjusted* -0.20 
-
0.61 0.20 0.3   -0.11 
-
0.54 0.31 0.6 
 *adjusted for maternal age at delivery 
 
 
 
 
  
  
 
Table 6. Regression models of total loge (AOSI+1) scores and early (early prenatal) and 
later (late prenatal/early postpartum) TCS/TCC product use adjusted for maternal age 
stratified by sex and cord blood testosterone above and below 4
th
 quartile. 
  
Early prenatal period  
(n=168)   
Late prenatal/ early  
postpartum period  
(n=142) 
Stratified by 
estimated 
regression 
coefficient 95 % CI 
P-
val 
 
estimated 
regression 
coefficient 95 % CI 
P-
val 
Sex* 
         Female -0.42 -1.0 0.2 0.2 
 
-0.10 -0.8 0.6 0.8 
Male -0.05 -0.6 0.5 0.9 
 
-0.10 -0.6 0.4 0.7 
Cord blood testosterone^                  
<4th  overall QT 
(n=125;107) -0.07 -0.5 0.4 0.8 
 
-0.02 0.5 0.5 0.9 
≥4th  overall QT (n=43;35) -0.79 -1.7 0.1 0.1  -0.46 -1.4 0.5 0.3 
<4th female QT 
(n=88;76) -0.10 -0.7 0.5 0.7 
 
-0.03 -0.6 0.5 0.9 
≥4th  female QT (n=80;66) -0.20 -0.8 0.4 0.5 
 
-0.25 -0.9 0.4 0.5 
< 4th  male QT 
(n=145;123) -0.16 -0.6 0.3 0.5   -0.09 -0.6 0.4 0.7 
≥4th  male QT (n=23;19) -1.10 -2.6 0.4 0.1   -0.24 -1.3 0.9 0.7 
 *test for heterogeneity of effect by sex: early prenatal period (P=0.4), late prenatal/early 
postpartum (P=1).  ^ test for heterogeneity of effect by testosterone level below and above 4
th
 
quartile: overall: early prenatal period (P=0.2), late prenatal/early postpartum (P=0.4); female: 
early prenatal period (P=0.8), late prenatal/early postpartum (P=0.5); male: early prenatal period 
(P=0.3), late prenatal/early postpartum (P=0.8). All models adjusted for mother‟s age at delivery. 
  
  
 
Table 7. Early prenatal triclosan (TCS) and triclocarban (TCC) containing products use 
by 36 months clinical ASD diagnosis (n=80). 
36 month 
outcome  Early prenatal period^ 
 
Late prenatal/early postpartum 
period^ 
  Nonuser TCS/TCC product users 
 
Nonuser TCS/TCC product users 
ASD* 27% 12% 
 
0 16% 
 
(n=3) (n=9) 
 
(n=0) (n=12) 
Non-TD 45% 48% 
 
80% 44% 
 
(n=5) (n=35) 
 
(n=4) (n=33) 
TD 27% 40% 
 
20% 40% 
  (n=3) (n=29) 
 
(n=1) (n=30) 
 ^ χ2 test across classification:  early prenatal period (P=0.39), late prenatal/early postpartum 
period (P=0.27)  
  
  
 
FIGURES 
 
Figure 1. The distribution of triclosan- and triclocarban-containing products reported 
according to NIH and EPA (n=217) by catetories. 
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APPENDIX 
 
Table 1.  List of triclosan (TCS) and triclocarban (TCC) containing products from „Household 
Product Database‟ (NIH) and „CPCat: Chemical and Product Categories‟ (EPA) with 
concentration information. 
source Ingredient percent Product Name 
NIH TCS 0.3 Bath & Body Instant AntiBacterial Hand Gel-Freesia 
NIH TCS 0.3 Revlon ColorStay LipSHINE Lipcolor Plus Gloss, Solar 
NIH TCS 0.1 Ultra Dawn Dishwashing Liquid and Antibacterial Hand Soap-02/10/2008 
NIH TCS 0.1 
Ultra Dawn Liquid Hand Dishwashing Liquid Plus Antibacterial Hand Soap, 
Apple Blossom 
NIH TCS 0.1 
Ultra Joy Mandarin Orange Splash Dishwashing Liquid and Antibacterial Hand 
Soap 
NIH TCS 0.3 Noxzema Triple Clean Antibacterial Lathering Cleanser-Old Product 
NIH TCS 0.3 Noxzema Triple Clean Antibacterial Lathering Cleanser-08/01/2007 
NIH TCS 0.3 Colgate Total 12-Hour MultiProtection Toothpaste Plus Whitening Gel 
NIH TCC 0.1-0.5 Avon Black Suede Talc Powder 
EPA TCS 0.006 ANTI-BACTERIAL SOAP SANITIVA 
EPA TCS <1% MICRELL ANTIBACTERIAL LOTION SOAP 
EPA TCS <1% KODAK CLINASEPT ANTIMICROBIAL SOAP 
EPA TCS <1% 9752 PURELL ANTIBACTERIAL LOTION SOAP 
EPA TCS <1% 7188 PURELL ANTIBACTERIAL LOTION SOAP 
Company 
Website TCS 0.3 Cetaphil antibacterial cleansing bar 
Company 
Website TCS 0.12 palmolive ultra antibacterial concentrated dish liquid orange 
Company 
Website TCS 0.25 Clean and Clear foaming facial cleanser 
Company 
Website TCS 0.46 
up & upn Foaming Hand Soap 
Company 
Website TCS 0.15 CVS antibacterial hand soap 
  
 
Table 2. Unadjusted regression models of total loge (AOSI+1) scores and early (early 
prenatal) and later (late prenatal/early postpartum) TCS or TCC product use in each 
category. 
  
Early prenatal period  
(n=168)   
Late prenatal/ early  
postpartum period  
(n=142) 
TCS/TCC product 
categories 
estimated 
regression 
coefficient 95 % CI 
P-
val 
 
estimated 
regression 
coefficient 95 % CI 
P-
val 
Dish soaps -0.02 -0.26 0.22 0.9 
 
0.03 -0.21 0.28 0.8 
Antibacterial 
soaps 0.10 -0.13 0.33 0.4 
 
-0.03 -0.28 0.22 0.8 
Body/face soaps 0.07 -0.22 0.36 0.6 
 
-0.05 -0.45 0.34 0.8 
Toothpastes -0.01 -0.24 0.22 0.9  0.11 -0.14 0.37 0.4 
 
  
  
 
Figure 1. Scatter plot of total AOSI score and total number of TCS/TCC products 
reported in early prenatal period (Spearman‟s rho).  
 
 
 
 
Figure 2. Scatter plot of total AOSI score and total number of TCS/TCC products 
reported in late prenatal/early postpartum period (Spearman‟s rho).  
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Figure 3. Scatter plot of total AOSI score and total number of TCS/TCC products 
reported in both early prenatal and late prenatal/early postpartum period (Spearman‟s 
rho).  
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CHAPTER 5. CONCLUSIONS 
  
 
SUMMARY OF FINDINGS 
 
Despite long known sex differences in ASD prevalence, the underlying etiologic 
mechanisms driving this are largely unknown.  The goal of this dissertation was to 
examine whether differences in prenatal testosterone levels, which are associated with 
sex, are also associated with ASD and to explore whether an environmental exposure 
influencing the developmental effects of endogenous androgens might be related to ASD 
phenotype in this cohort. 
The project had three components. First, meconium was explored as a novel 
matrix for measuring prenatal androgens.  Meconium is universally accessible biosample 
available in large quantities.  Results from androgen assays in meconium were compared 
to results from androgen measurement in cord blood from the same maternal-child dyads. 
Second, the association between cord blood testosterone and early ASD-related 12 month 
phenotype was estimated in a high ASD risk pregnancy cohort (Chapter 3).  Finally, the 
relationship between prenatal exposure to widely used antimicrobials with suspected 
androgenic activity and ASD-related phenotypes was also assessed in the same high ASD 
risk pregnancy cohort.  
All three studies used the Early Autism Risk Longitudinal Investigation (EARLI) 
cohort, a high autism risk cohort following pregnant mothers who previously had a child 
with ASD diagnosis (autistic disorder, Asperger syndrome or pervasive developmental 
disorder not otherwise specified).  Based on the fact that ASD recurrence in siblings of 
children with ASD is manifold higher the general population prevalence, we expect 
  
 
greater manifestation of ASD-related phenotype and higher occurrence of clinical ASD in 
this enriched risk pregnancy cohort. All the reported work here capitalized on 
prospectively collected biologic samples and extensive exposure information reported the 
critical etiologic windows and the availability of early quantitative ASD-related 
phenotype data.   
One of the major limiting factors in studying prenatal androgen effects on ASD 
development is a lack of safe and accurate method for determining androgen exposure in-
utero.  Fetal androgen production is variable throughout gestation, compounding that 
with a generally short serum half-life, makes complete assessments difficult.  Two 
established method for estimating fetal androgen exposure have been reported.  Auyeung 
et. al used mid-trimester amniotic fluid obtained from amniocentesis.  Their study was 
the first to report an association between androgen concentration and ASD development.  
However, their method is invasive and multiple samples throughout the pregnancy would 
need to be collected to determine the overall exposure risk. Therefore, this method cannot 
translate to routine androgen assessment in the general population.  The second approach 
that has been used involves umbilical cord blood collection at the time of delivery.  The 
single study published thus far using this approach did not find an association between 
cord blood androgen level and ASD traits measured in adulthood.  However, in addition 
to limitations associated with later in life phenotype evaluation, as noted earlier, serum 
androgen levels only provide a limited window of information at the time of collection.  
In this case, the androgen concentrations only reflect those immediately preceding 
delivery.  In Chapter 2, a third method of to determine in-utero androgen exposure was 
investigated.  Meconium measurement of androgen has two advantages over the existing 
  
 
approaches.  First, collection is non-invasive and can be done postpartum.  Second, 
meconium as a medium of inactive waste storage potentially correlates to the fetal 
exposure of androgens throughout in-utero development.  
Meconium total androgen levels were quantified and compared to cord blood 
androgen levels. The results showed that both meconium and cord blood may be suitable 
mediums for estimating prenatal androgen level, based on evidence of detection, sex 
difference and variability. Androgens were detected in larger quantities in meconium 
with greater testosterone sex difference.  However, low correlations were found between 
meconium and cord blood androgen levels. This lack of correlation may well reflect 
anticipated difference in the captured exposure window.  Although meconium and cord 
blood are both collected after birth, meconium samples were collected within 24 hours 
while cord blood samples were collected soon after birth. In addition, greater testosterone 
sex differences were observed between earliest meconium samples compared to the later 
samples, however, interpretation is limited due to unknown sample sequence.    Cord 
blood androgen levels in this enriched risk study population were comparable previously 
reported general population levels (Keelan et al., 2012; Kuijper, Ket, Caanen, & 
Lambalk, 2013) suggesting findings may generalize beyond cohorts like EARLI.   
Analysis in Chapter 2 established meconium as a viable medium for determining 
in-utero androgen exposure. However, umbilical cord blood is still currently the most 
accessible and widely-used bio-sample for determining androgen levels.  One previous 
study focused on a low-risk generalized population and did not show an association 
between androgen levels and ASD related traits assessed in adults. In Chapter 3, the 
  
 
association between cord blood androgen level and ASD risk is revisited using in the high 
risk EARLI cohort. This was the first investigation of the association between prenatal 
androgen exposure and early autism-related phenotype among infant siblings of older 
children previously diagnosed with ASD.  We found elevated umbilical cord testosterone 
level was associated with a weak increase in 12 month AOSI score. This finding is 
consistent with previous studies using amniotic fluid samples in general populations 
(Auyeung et al., 2012; Auyeung et al., 2009; Auyeung, Taylor, Hackett, & Baron-Cohen, 
2010). Interestingly, a stronger association of prenatal testosterone and ASD risk was 
found among subjects with female proband, which persisted in sensitivity analyses using 
36 month ASD measures.   
The mechanism involving testosterone likely requires multiple genes to increase 
endogenous testosterone and also increase the brain‟s susceptibility to testosterone at the 
same time. The multi-factorial multi-threshold model of ASD suggests that female sex is 
in general protective against ASD and therefore affected females are more likely to have 
increased etiological/genetic load (Lai, Lombardo, Auyeung, Chakrabarti, & Baron-
Cohen, 2015).  Therefore, heterogeneity of effect by proband sex may be related to the 
inheritance- pattern of ASD risk genes.  Some related to prenatal testosterone pathways, 
such as synthesis, transport, metabolism or feedback mechanisms.  It is also possible that 
additional genes that increase androgen receptor number or affinity, such as androgen 
receptor polymorphism, could create heterogeneity in response to prenatal testosterone 
levels. One explanation may be that testosterone pathway genetic mutations can only be 
activated with a presence of another etiological/genetic factor that is over-transmitted to 
females with ASD.  For instance, there may be a female specific mutation that lowers 
  
 
testosterone threshold and increased ASD risk would be observed only when mutations in 
testosterone pathway are also present.  Multiplex families with affected females may also 
have some general enrichment for these genetic variants. Therefore, in these families, 
children, regardless of sex, are more likely to have ASD that was etiologically influenced 
by prenatal androgens.   
While Chapter 3 demonstrated the plausibility of endogenous testosterone being 
associated with ASD, there is keen interest in determining if exogenous environment 
plays key role in ASD etiology.  As previously stated, there are likely parallel 
mechanisms for triggering the development of ASD.  Certainly not all possible causes are 
related to androgen exposure.  However, there are known environmental chemicals that 
demonstrate in-vitro and in-vivo androgenic activity. Exposure to these chemicals in-
utero or postpartum may modulate an individual‟s ASD risk. This concern was the main 
focus of Chapter 4, which describes the relationship between antimicrobial agents, 
triclosan (TCS) and triclocarban (TCC), and early autistic phenotype.   Two in vitro 
studies using human breast cancer cell lines found TCS activates androgen receptor (Ahn 
et al., 2008; Christen, Crettaz, Oberli-Schrammli, & Fent, 2010), however, TCC activates 
androgen dependent transcription without binding to androgen receptor (Chen et al., 
2008). TCS and TCC are typical ingredients incorporated into widely used antimicrobial 
personal care products. 75% of US population have detectable amount of TCS in urine 
and TCS metabolites have also been detected in breast milk, amniotic fluid, and serum 
TCS and TCC exposure was determined using personal care product name reported 
during the EARLI home visit interview and linked to two public TCS/TCC containing 
personal care product database. Findings from this investigation did not support an 
  
 
association between early prenatal and late prenatal/early postpartum use of TCS or TCC-
containing products and ASD.  
This initial investigation of TCS/TCC exposure to ASD-related phenotype faced a 
series of challenges.   The self-report exposure assessment was vulnerable to 
measurement error arising from unreported/unknown exposure, incomplete TCS/TCC 
source product list, and data entry and text matching error.  Further because of the 
dichotomization of exposure the high prevalence of any TCS/TCC exposure as assessed 
by our method her, reduced the power to detect differences in AOSI across TCS/TCC 
exposure.   Initial power analyses were done assuming availability of TCS and TCC 
biomarkers, which were not able to be obtained due to limited resources.  
Overall, the approach used in this series of analyses had several important 
strengths.  The prospective design reduces concerns over differential exposure 
misclassification common in retrospective, recall-based exposure measurement.  In two 
out of three studies included in this dissertation, a range of potential confounding 
variables were considered and when appropriate, adjusted for, through multivariable 
regression methods.  Proband and sibling sex were considered as potential effect 
modifiers.  
Different etiologic factors may contribute to various traits included in 
dichotomous diagnosis criteria in a complex disorders, such as ASD, with wide of signs, 
symptoms and levels of severity. Early ASD-related phenotype was assessed using  the 
AOSI, a semi-structured direct observational measure using visual tracking and attention 
disengagement, coordination of eye gaze and action, imitation, affective responses, early 
  
 
social-communicative behaviors, behavioral reactivity, and sensory motor development 
(Bryson, Zwaigenbaum, McDermott, Rombough, & Brian, 2008).  Generally, ASD 
assessment at age three or later has been standard in autism research. However, evidence 
has been accumulating in the stability of ASD classification made at earlier ages (Sagiv, 
Kalkbrenner, & Bellinger, 2015) and a recent study found significant correlation between 
14 months AOSI and 36 month ADOS score (r=0.4, P=0.005) (Gammer et al., 2015).    
FUTURE DIRECTIONS 
A limited number of studies has examined testosterone dependent ASD risks. 
Three such studies have measured testosterone level in amniotic fluid and one study 
measured testosterone in cord blood. No study, other than the work reported here, 
estimated the association between prenatal androgen levels and ASD risk in an enriched 
risk cohort.    Our findings suggest that prenatal testosterone level may play a role in the 
etiology of ASD , especially in families with female ASD in their pedigree. However, the 
initial exploration of prenatal exposure to two potential environmental androgen agonists, 
triclosan and triclocarban, did not support an association with ASD risk.  
We detected large quantities of conjugated and unconjugated androgens in 
meconium.  The potential for meconium to serve as a matrix capturing cumulative 
prenatal androgen exposure is promising; however, more work is needed to better 
characterize variation in meconium androgen level by collection time.   The collection of 
a complete sample of all meconium passed from birth to the emergence of first milk stool 
would enable measurement of within subject variation by collection time. It is important 
  
 
to understand within subject variability to correctly interpret androgen levels in 
meconium.    
The finding of proband sex effect modification of the association between 
prenatal testosterone and ASD risk need to be replication, which would most easily be 
accomplished in other enriched risk cohorts. Although the heterogeneity of effect by 
proband sex persisted when considering 36 month outcomes in this sample, this finding 
also needs to be replicated in future analyses.   In the meantime, there may also be 
opportunities to conduct targeted candidate gene, or pathway analyses, in large databases 
of multiplex families that have been assembled and continue to grow in ASD research 
(Brimberg, Sadiq, Gregersen, & Diamond, 2013).  
Despite the initial finding of no association, further work focused on improved 
measurement of prenatal TCS and TCC exposure could still contribute to future research 
on environmental influences on neurodevelopment.  We found that existing public data 
on TCS/TCC containing consumer products is limited, hindering the potential to measure 
these exposures through self-report data.  Biosampling strategies have been developed for 
TCS and TCC exposure (Calafat, Ye, Wong, Reidy, & Needham, 2008) and the 
integration of these into epidemiologic studies of neurodevelopmental outcomes is 
encouraged.  Biosampling data could also be leveraged to conduct validation self-report 
TCS/TCC exposure assessment approaches that develop as product database information 
potentially expands.  
In conclusion, the work in this dissertation suggests that a priority for future study 
related to prenatal androgen exposure and ASD is the elucidation of possible etiologic 
  
 
mechanisms involving in testosterone pathway, especially in families with history of 
female ASD that could involve replication of some of the work done here, leveraging of 
existing genomics databases, and further work developing, validating, and applying better  
measures of potential external influences on testosterone-mediated neurodevelopmental 
pathways.    
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METHODS APPENDIX 
  
 
1. Simulation study of different meconium collection methods 
 
Meconium is a biomarker matrix that has potential to assess cumulative exposures 
in epidemiologic studies of prenatal risk factors. Depending on when meconium is 
collected, different exposure windows during pregnancy can be measured. However, little 
guidance exists regarding the extent to which timing of meconium collection will 
influence resulting effect estimates. Simulation was used to estimate various bias that 
may result from using different meconium collection methods and this lead to publication 
which is included.  
  
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
2. Meconium Pilot Study 
 
Epidemiological studies of prenatal exposure biomarkers commonly use maternal 
urine and blood or fetal cord blood. However, these matrices often capture transient 
exposures and may not always allow for measurement of cumulative fetal exposures 
across the etiological time window of interest.  In contrast, concentrations of analytes in 
meconium are thought to represent accumulated exposures during the period of 
meconium formation over the pregnancy because meconium may be metabolically inert.   
A meconium begins forming in the 13th week of gestation (Bearer, 2003), around the 
time of the fetal testosterone surge.  Meconium is preferred over urine or blood in 
detecting some prenatal exposures due to non-invasive collection and longer detection 
window (Kwong & Ryan, 1997).  Moreover, meconium accumulation throughout 
pregnancy results in greater quantities compared to other biomarkers (Marin, Christensen, 
Baer, Clark, & McMillin, 2011).    
Meconium has the potential to capture cumulative androgen level through late 
gestation. Fetal androgens enter meconium from cycles of swallowed or inhaled amniotic 
fluid, shed epithelial cells, intestinal secretions and urine (fetal urine begins deposition in 
the amniotic fluid in the 11th gestational week) and is generally not excreted until the 
delivery with complete excretion within 2 to 4 days (Newman & Antonakopoulos, 1989; 
Ortega Garcia, Carrizo Gallardo, Ferris i Tortajada, Garcia, & Grimalt, 2006).  However, 
meconium has yet to be studied as a matrix for prenatal testosterone assessment.  Thus, a 
pilot study was designed to determine whether androgens could be detected in meconium 
  
 
collected from postpartum mothers at the hospital  and to explore whether storage time 
impacts measured androgen levels . 
Methods 
Subjects were consented upon arrival of labor and delivery at Hahnamann 
University hospital.  The first meconium sample was collected from mothers. Meconium 
samples less than 3g were excluded. Total of 8 samples were collected and each sample 
was thoroughly mixed with spatula and split into three aliquots with approximately 1g 
respectively. All the aliquots were centrifuge briefly distribute meconium.   Two out of 
three aliquots were spiked with known amount of low and high androgen (Testosterone, 
Androstenedione and DHEA) solutions.   The high level spiking solution was prepared by 
dissolving 0.01g in 30 ml ethanol to make 330 ng/uL. The 0.3 high level spiking solution 
was then diluted 1:10 to make a 33 ng/uL low spiking solution.  For every gram of 
meconium, 3 uL of either low or high spike solution was added. Meconium samples were 
spiked in two batches in November and December of 2013 and then stored in -2C freezer. 
Meconium samples were refrigerated for 6 to 13 days and spiked in two batches (four 
samples each) which were then stored in repositories for 315 to 339 days (Table 1).  All 8 
samples were batch shipped to Johns Hopkins biorepository (JHBR) and were processed 
similarly to the Early Autism Risk Longitudinal Investigation (EARLI) meconium 
samples.  Samples were shipped to JHBR on January 13, 2014 and one freeze-thaw cycle 
was performed without splitting samples to mimic EARLI procedures. Samples were then 
stored at the repository then went through one additional freeze-thaw cycled to send 1g to 
a lab in Australia to develop meconium androgen assay on October 10, 2014. Remaining 
  
 
samples were then sent to Drexel University lab and was stored in freezer. Samples were 
thawed 1g was used for analysis on January 14, 2015. Androgen levels were then 
measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay.  
Results 
There were two females and six males in the pilot (Sample ID 299000 and 299006). 
Androgens were measured in all samples. Refrigeration time differences did not affect 
the androgen levels. Spiking patterns were detected and most samples (Figures 1-3).  
Except in two samples (Sample ID 299000 and 299001) T, AD and DHEA levels were 
consistently higher in high spiked sub aliquots (Figure 1-3).  Females had greater 
androgen level than males (Table 2).  However, given the very small sample size, this 
could easily be attributable to sampling error. Androgen levels were different between the 
two batches. 
Conclusion 
Androgens were successfully detected in meconium samples in both sexes. Androgen 
levels appear to be not affected by storage time in refrigeration. However, we observed 
batch effect on androgen level. Variations in preparing the spiked solution between the 
batches may explain some of the differences observed between the two batches. Greater 
androgen level was detected among females but numbers were small (n=2) and it would 
need to be further investigated with larger samples.  
 
  
  
 
Table 1. Description of samples characteristics. 
sample 
ID Collection Date Spike Date Storage days Freeze days 
299000 12/10/2013 12/16/2013 6 315 
299001 12/10/2013 12/16/2013 6 315 
299002 12/10/2013 12/16/2013 6 315 
299003 12/11/2013 12/16/2013 5 315 
299004 11/16/2013 11/22/2013 6 339 
299005 11/13/2013 11/22/2013 9 339 
299006 11/9/2013 11/22/2013 13 339 
299007 11/9/2013 11/22/2013 13 339 
 
 
 
  
  
 
Table 2. Testosterone (T), androstenedione (A4) and Dehydroepiandrosterone (DHEA) 
measure in meconium samples.  
    n Mean 
Std. 
Dev. Min Max 
Total T   8 79.5 61.6 11.4 177.2 
 
A4   8 301.4 188.0 142.1 694.8 
 
DHEA   8 3126.5 3767.9 457.7 11545.7 
Female T   2 115.1 87.8 53.0 177.2 
 
A4   2 464.7 325.4 234.6 694.8 
 
DHEA   2 6187.2 7578.1 828.7 11545.7 
Male T   6 67.7 55.6 11.4 141.8 
 
A4   6 246.9 118.5 142.1 408.5 
 DHEA   6 2106.3 1842.3 457.7 5512.8 
 
  
 
Figure 1. Testosterone level (nmol/g) of sub aliquots by subjects.  
 
 
 
Figure 2. Androstenedione level (nmol/g) of sub aliquots by subjects.  
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Figure 3. Dehydroepiandrosterone (DHEA) level (nmol/g) of sub aliquots by subjects.  
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3.  Meconium Total Androgens Methods 
 
Amniotic fluid and cord blood have been used to measure prenatal fetal androgen levels. 
However, meconium has yet to be explored as a fetal androgen matrix. Here we describe 
in detail meconium total androgen assay methods used in Chapter 2.  
 
Meconium extraction 
To quantify steroid hormones in meconium, approximately 50 mg (average 50.6 mg) of 
each meconium sample was weighed out into pre-tared 1.5 mL plastic snap cap vials.  
The wet weight of meconium was recorded to 0.1 mg on a balance with accuracy to +/- 
0.01 mg. 20 µL of internal standard (10 pg/uL 
13
C3-testosterone, 10 pg/uL 
13
C3-
androstenedione, and 50 pg/uL 
2
H5- dehydroepiandrosterone in methanol) were added to 
each sample.  Sample extraction was performed by addition of 1.2 mL methanol, 
followed by 30 minutes vortexing and 10 minutes sonication in a water bath at room 
temperature. Samples were centrifuged at 10,000 rcf for 10 minutes, after which 
methanol was transferred into 15 mL screw cap glass vials. This extraction was then 
repeated with a fresh 1.2 mL of methanol and the methanolic extracts for each sample 
were combined.  
Analysis of total steroids 
Enzymatic deconjugation of the androgen samples was performed as previously 
described (23851165) using β-glucuronidase from Escherichia coli, Type VII-A (Sigma-
Aldrich, cat# G7646) and Sulfatase from abalone entrails, Type VIII (Sigma-Aldrich, 
  
 
cat# S9754). The sulfatase (1,000 U/vial) and β-glucuronidase (500,000 U/vial) were 
each re-suspended separately in 2 mL of 100 mM sodium acetate to produce stocks of 
500 U/mL sulfatase and 250,000 U/mL β-glucuronidase. The β-glucuronidase stock was 
further diluted in 100 mM sodium acetate to produce a 1250 U/mL working solution. To 
begin, 100 µL aliquots of the previously collected methanolic meconium extracts were 
transferred to new 15 mL screw-top vials. To these aliquots were added 48 µL sulfatase 
(24 U) and 120 µL β-glucuronidase (150 U). Samples were incubated at 37°C for 6 hours 
prior to addition of a second 48-µL aliquot of sulfatase (a second 24 U) and overnight 
incubation at 37°C. After 24 hours from the initial enzymatic addition, 200 µL water was 
added to each sample, followed by 2 mL of 3:2 hexanes:dichloromethane. Samples were 
then extracted by hexane:dichloromethane, derivatized by Girard‟s reagent P, and 
resuspended for LC-MS analysis as above.  
LC-MS/HRMS Analysis 
LC-MS/HRMS analysis on the Girard P derivatives of testosterone, androstenedione, and 
dehydroepiandrosterone were conducted on an Ultimate 3000 quaternary UPLC equipped 
with a refrigerated autosampler (6°C) and a column heater (60°C) coupled to a Thermo 
QExactive Plus HRMS.  LC separations were conducted on a Phenomenex Kinetix 
biphenyl column (2.6 µm, 100 A, 100 x 2.1 mm).  A multi-step gradient at 0.2 mL/min 
flow with solvent A (Water 1% acetic acid) and solvent B (acetonitrile 1% acetic acid) 
was as follows; 20% B from 0 to 1 minute, increasing to 25% B from 1 to 5 minutes, 
increasing to 100% B from 5 to 8 minutes then holding 100% B until 12 minutes, then the 
column was returned to starting conditions and re-equilibrated at 20% B from 13 to 17 
  
 
minutes.  The mass spectrometer was operated in positive ion mode alternating between 
full scan (200-800 m/z) at a resolution of 70,000 and parallel reaction monitoring at 
17,500 resolution with a precursor isolation window of 0.7 m/z.  Molecular (MH
+
) 
precursor and product ions were as follows; testosterone and dehydroepiandrosterone 
(422.2802 to 343.2380), androstenedione (420.2646 to 341.2224), 
13
C3-testosterone 
(425.2903 to 346.2481), 
13
C3-androstenedione (423.2746 to 344.2324), and 
2
H5- 
dehydroepiandrosterone (428.3179 to 349.2757).  All steroids were completely resolved 
by chromatography with retention times of 6.2 min, 8.2 min and 9.8 min for 
dehydroepiandrosterone, testosterone, and androstenedione, respectively.  Stable isotope 
analogs co-eluted exactly with the analyte, except for 
2
H5-dehydroepiandrosterone which 
eluted at 0.1 min earlier than dehydroepiandrosterone.  Confirmatory analysis of all 
parallel reaction monitoring peaks revealed similar response ratios for analytes across all 
samples, indicating similar specificity in scan types.  Therefore, all analytes were 
quantified based on the MH
+
 within a 5 ppm window, except 
13
C3-testosterone which 
exhibited improved peak characteristics (signal-noise) with parallel reaction monitoring.   
 
 
 
 
 
  
4. Triclosan and triclocarban containing product list 
 
List of triclosan and triclocarban containing product list was needed to determine 
triclosan and triclocarban product used based on subject reported product names. Two 
publically available sources ,National Institutes of Health „Household Product Database‟ 
website and US Environmental Protection Agency „CPCat: Chemical and Product 
Categories‟ websites, were used to determine triclosan and triclocarban containing 
product use in Chapter 4 analyses.  The complete list of trcilosan and triclocarban 
containing products extracted in December 2014 is included below.  
Table 1.   List of triclosan (TCS) and triclocarban (TCC) containing products from 
„Household Product Database‟ (NIH) and „CPCat: Chemical and Product Categories‟ 
(EPA). 
Ingredient Source Product Name 
TCS NIH Bath & Body Instant AntiBacterial Hand Gel-Freesia 
TCS NIH Lever 2000 Soap Bar Antibacterial 
TCS NIH Lever 2000 Deodorant Soap Bar 
TCS NIH Suave Deodorant Soap, Antibacterial 
TCS NIH Dial Antibacterial Body Wash, Spring Water-08/21/2009 
TCS NIH Dial for Men, 3D Odor Defense Body Wash 
TCS NIH 
Dial All Day Freshness Antibacterial Body Wash with Moisturizers, Lavender & 
Twilight Jasmine 
TCS NIH Dial for Men 3-D All Day Odor Defense Body Wash, Odor Control Agents 
TCS NIH Dial Antibacterial Body Wash, Mountain Fresh-08/21/2009 
TCS NIH Dial All Day Freshness Antibacterial Body Wash with Moisturizers, Spring Water 
TCS NIH Right Guard Total Defense 5, 5-in-1 Deodorizing Body Wash, Power Scrub 
TCS NIH Softsoap Gentle Antibacterial Body Wash with Vitamins 
TCS NIH Softsoap Liquid Antibacterial Body Soap 
TCS NIH Revlon ColorStay LipSHINE Lipcolor Plus Gloss, Blast 
TCS NIH Revlon ColorStay LipSHINE Lipcolor Plus Gloss, Dazzle 
TCS NIH Revlon ColorStay LipSHINE Lipcolor Plus Gloss, Solar 
-continued 
  
 
Ingredient Source Product Name 
TCS NIH Avon X-Series Deodorant Body Spray, Quake 
TCS NIH Avon X-Series Deodorant Body Spray, Flash 
TCS NIH von X-Series Deodorant Body Spray, Rush  
TCS NIH Old Spice Classic Stic-Original Scent-Old Product 
TCS NIH Old Spice Classic Stic-Original Scent-01/01/2008 
TCS NIH Old Spice Red Zone Antiperspirant & Deodorant-Old Product 
TCS NIH Right Guard Sport Deodorant, Aerosol, Fresh Scent-02/25/2009 
TCS NIH Right Guard Sport, Deodorant Aerosol, Fresh-Old Product 
TCS NIH Right Guard Sport, Clear Stick Deodorant, Original-Old Product 
TCS NIH Right Guard Sport Deodorant, Aerosol, Original-02/25/2009 
TCS NIH Right Guard Sport, Deodorant Aerosol, Original-Old Product 
TCS NIH Shield Deodorant Soap Bar, Surf Scent 
TCS NIH Soft and Dri PowerStripe Invisible Solid Antiperspirant, Passion Flower 
TCS NIH 
Dawn Hand Soap Dishwashing Liquid, Ultra Concentrated, Antibacterial, Apple 
Blossom 
TCS NIH Dawn Powerscrubbers Plus Antibacterial Diswashing Liquid, Orange Scent  
TCS NIH Ultra Dawn Dishwashing Liquid and Antibacterial Hand Soap-02/10/2008 
TCS NIH 
Dawn Hand Soap Dishwashing Liquid, Ultra Concentrated, Antibacterial, Orange 
Scent 
TCS NIH Ultra Dawn Dishwashing Liquid and Antibacterial Hand Soap 
TCS NIH 
Ultra Dawn Liquid Hand Dishwashing Liquid Plus Antibacterial Hand Soap, Apple 
Blossom 
TCS NIH 
Ultra Joy Mandarin Orange Splash Dishwashing Liquid and Antibacterial Hand 
Soap 
TCS NIH Joy Dishwashing Liquid, Mandarin Orange Splash  
TCS NIH Clearasil Daily Face Wash, Sensitive Skin 
TCS NIH Clearasil Daily Face Wash-discontinued 
TCS NIH Clearasil Stayclear Daily Face Wash, Oil-Free 
-continued- 
  
 
Ingredient Source Product Name 
TCS NIH Imina Lathering Facial Cleanser-Old Product 
TCS NIH Noxzema Triple Clean Antibacterial Lathering Cleanser-Old Product 
TCS NIH Noxzema Triple Clean Anti-Bacterial Lathering Cleanser 
TCS NIH New Vaseline Brand Intensive Care Antibacterial Hand Lotion-discontinued 
TCS NIH Avon Naturals Cucumber Melon Body Spray 
TCS NIH Avon Naturals Pomegranate & Mango Refreshing Body Spray 
TCS NIH Avon Naturals Lemon Blossom & Basil Juicy Moisture Body Spray 
TCS NIH Avon Naturals Vanilla Soy Milk Body Spray 
TCS NIH Edge Advanced Shave Gel, Ultra Sensitive Skin (Unscented)-04/30/2009 
TCS NIH Gillette Complete Skincare Multi-Glide Shave Gel-01/01/2008 
TCS NIH 
Colgate Total Advanced Toothpaste, Anticavity Fluoride and Antigingivitis, Deep 
Clean, -05/15/2012 
TCS NIH Colgate Total Toothpaste-Old Product 
TCS NIH Colgate Total 12-Hour MultiProtection Toothpaste Plus Whitening Gel 
TCS NIH 
Colgate Total Advanced Toothpaste, Anticavity Fluoride and Antigingivitis, Fresh + 
Whitening, Fresh  
TCS NIH Colgate Total Toothpaste, Fresh Stripe 
TCC NIH Coast Deodorant Bar Soap-Original Scent-Old Product 
TCC NIH Dial Antibacterial Bar Soap, White-03/11/2009 
TCC NIH Dial for Men Bar Soap, Full Force-03/11/2009 
TCC NIH Dial for Men, 3D Odor Defense Bar Soap 
TCC NIH Dial Antibacterial Deodorant Soap-Old Product 
TCC NIH Dial Antibacterial Bar Soap, Gold-03/11/2009 
TCC NIH Dial for Men Bar Soap, Blue Grit-03/11/2009 
TCC NIH Dial for Men Bar Soap, Recharge-03/11/2009 
TCC NIH Dial Antibacterial Deodorant Bar Soap, Mountain Fresh-Old Product 
TCC NIH Irish Spring Deodorant Bath Bar, Sport-02/15/2007 
TCC NIH Safeguard Antibacterial Bar Soap, Beige-11/01/2009 
-continued- 
  
 
Ingredient Source Product Name 
TCC NIH Safeguard Antibacterial Deodorant Soap-Old Product 
TCC NIH Safeguard Antibacterial Deodorant Soap, Beige-01/01/2008 
TCC NIH Safeguard Antibacterial Deodorant Bar Soap-Old Product 
TCC NIH Zest Deodorant Bar Soap, Whitewater Fresh-Old Product 
TCC NIH Avon Black Suede Talc Powder 
TCS EPA English Leather After Shave 
TCS EPA SEP-GUARD 1518 
TCS EPA STA-LUBE HAND CLEANER 
TCS EPA ANTI-BACTERIAL SOAP SANITIVA 
TCS EPA MICRELL ANTIBACTERIAL LOTION SOAP 
TCS EPA BACTERIOSTATIC DUST ABSORBER, 1424 
TCS EPA BACTERIOSTATIC DUST ABSORBER, 1335 
TCS EPA BACDOWN HANDSOAP FORMULATION 
TCS EPA KODAK CLINASEPT ANTIMICROBIAL SOAP 
TCS EPA 9212-12 DERMAPRO ANTIMICROBIAL LOTION SOAP 
TCS EPA 9752 PURELL ANTIBACTERIAL LOTION SOAP 
TCS EPA 9751 PURELL ANTIBACTERIAL LOTION SOAP 
TCS EPA 7188 PURELL ANTIBACTERIAL LOTION SOAP 
TCS EPA ULTRACLENZ ANTIBACTERIAL SOAP TF866D 
TCS EPA Dial CompleteÂ® Liquid Hand Soap 
TCS EPA Nexcare Cracked Heel Care 
TCS EPA Dial Complete Antibacterial Foaming Lotion Hand Wash (Kitchen) - ON HOLD 
TCS EPA SS Anti Bacterial Medicated complexion Bar 
TCS EPA Soft Care Foaming Antibacterial Hand Soap 
TCS EPA Insect bite Relief Applicator 
TCS EPA Insect Bite 300ct 
TCS EPA English Leather Black Deodorant 2007 Holiday 
-continued- 
  
 
Ingredient Source Product Name 
TCS EPA ANTONIO BANDERAS - BLUE SEDUCTION FOR MEN DESODORANTE SPRAY 
TCS EPA The San Diego Soap Company Orange Flower Honey Hand Soap 
TCS EPA The Invisible Armor, Inc. 
TCS EPA ANTONIO BANDERAS DEODORANT SPRAY 
TCS EPA High School Musical All for One Body Spray 
TCS EPA High School Musical Fast Break Body Spray 
TCS EPA Sun Sations Liquid Dish Ultra Detergent Citrus Anti-bac 
TCS EPA Salon Grafix Invisible Dry Spray Shampoo 
TCS EPA Moisturizing Antibacterial Hand Soap 
TCS EPA Moisturizing Antibacterial Hand Soap Sensitive Skin 
TCS EPA Aromasense Body Oil Rose Petals 
TCS EPA Heno de Pravia Deodorant 
TCS EPA Dr. Snapz Insect Bite Relief 
TCS EPA Heno de Pravia Talcum Powder 
TCS EPA The San Diego Soap Company Honey and Blackberry Hand Soap 
TCS EPA English Leather Classic Deodorant 2007 Holiday 
TCS EPA SS Anti Bacterial Medicated complexion Bar 
TCS EPA Nickelodeon Egg Moldable Soap 
TCS EPA Fisher-Price Play-Soap Mini Tubs SK 
TCS EPA Fisher-Price Stamper & Squirter Set PDQ 
TCS EPA Fisher-Price 3pcs Play-Soap Crayons SK 
TCS EPA Princess Modable Soap 
TCS EPA Disney Egg Moldable Soap 
TCC EPA SCENT-A-WAY Antibacterial Bar Soap 
TCS 
Company 
Website Bath and Body works antibacterial soap/gel/foam 
TCS 
Company 
Website 
Cetaphil antibacterial cleansing bar 
-continued- 
  
 
Ingredient Source Product Name 
TCS 
Company 
Website palmolive ultra antibacterial concentrated dish liquid orange 
TCS 
Company 
Website Clean and Clear foaming facial cleanser 
TCS 
Company 
Website 
up & up Foaming Hand Soap 
TCS 
Company 
Website CVS antibacterial hand soap 
 
  
  
 
5.  The Early Autism Risk Longitudinal Investigation (EARLI) home walkthrough survey 
personal care product use questions. 
 
Maternal interview were administered during second trimester prenatal and postpartum 
EARLI home visits.  The interview included questions on soaps (dish, hand, body and 
facial) and toothpastes use. Personal care product category specific questions are listed 
below. 
 
 EARLI Home Walkthrough Survey Personal Care Product Questions 
Dish soap   
1. [Since 3 months before you became pregnant until now / 
since your 1st Prenatal Home Visit], have you used dish soap 
to clean your dishes (not in the dishwasher)? 
2. What was the name of the dish soap and how full is the 
container? 
Antibacterial 
soap/ 
Waterless 
gels 
1. [Since 3 months before you became pregnant until now / 
since your 1st Prenatal Home Visit], did you use antibacterial 
soaps or waterless gels? 
2. Please either show me or tell me the name of the product and 
the typical amount you use. 
Body/Facial 
soap 
1. [Since 3 months before you became pregnant until now / 
since your 1st Prenatal Home Visit], did you use body or 
facial soap? 
2. Please either show me or tell me the name of the product and 
the typical amount you use. 
Toothpaste 
1. [Since 3 months before you became pregnant until now / 
since your 1st Prenatal Home Visit], did you use toothpaste? 
2. Please either show me or tell me the name of the product and 
the typical amount you use. 
 
 
  
  
 
6. Triclosan or triclocarban containing personal care product text matching  
 
Text matching strategy was applied to match publicly available triclosan and triclocarban 
containing products to the interview based self reported personal care products. Four 
criteria were explored with increasing specificity to match the reported personal care 
product name to the 127 TCS/TCC products. Level 1 classification was used in Chapter 4 
analysis.  
Table 1. Triclosan and triclocarban containing product exposure classification criteria. 
 Exposure 
classification 
Examples in dishsoap category 
Level 1 Product name 
 
Level 2 Lv 1 + “anti” 
 
Level 3 Lv 2 + product 
speficic keyword 
 
 
Level 4 Lv 3 + before 
disconinuation 
date 
 
 
  
 14.   dawn antibacterial u..                                     
                                                                  
 12.   ultra concentrated d..                                     
 11.   dawn advanced power                                        
  5.   dawn                     cascade (dish washer)             
  4.   dawn                                                       
  1.   dawn original scent                                        
 47.   gain ultra                    oxy   dawn antibacterial  
 43.   dawn antibacterial h..                                  
 31.   dawn antibacterial h..                                  
 22.   palmolive anti-bacte..                                  
 14.   dawn antibacterial u..                                  
 14.   dawn antibacterial ultra concentrated                        
 14.   dawn antibacterial ultra concentrated                        
  
 
Table 2.  TCS/TCS classification levels by early (early prenatal) and later (late 
prenatal/early postpartum) TCS/TCC product use. 
 TCS product Users (%) 
 
Early prenatal 
period 
Late prenatal/early 
postpartum period 
Overall 
Classification 
  
 
Level 1 89.06 73.44 93.53 
Level 2 37.5 26.04 49.41 
Level 3 17.71 7.29 21.18 
Level 4 15.63 6.25 18.82 
 
 
 
 
 
  
  
 
 
 
  
 
7. Additional validation of self-reported product based triclosan and triclocarban 
exposure during pregnancy using a validation study design 
 
To date, no validation study has been conducted comparing self-reported personal care product 
based triclosan (TCS) triclocarban (TCC) exposure to the „gold standard‟.  In Chapter 4 self-
report product use data was used to determine TCS and TCC exposure.  Here, we describe a 
potential validation study that could be conducted using EARLI data to validate TCS/TCC 
exposure. 
The Early Autism Risk Longitudinal Investigation (EARLI) study collects urine, serum and 
breast milk and detection of TCS has been reported in all of them.   TCS and TCC levels are most 
frequently measured in urine samples due to fast excretion (half-life less than 24 hours) and ease 
of collection (Calafat, Ye, Wong, Reidy, & Needham, 2008; Koch et al., 2014; Sandborgh-
Englund, Adolfsson-Erici, Odham, & Ekstrand, 2006; Scharpf, Hill, & Maibach, 1975). Rapid 
elimination may result in high within-individual and between-individual variations (Koch et al., 
2014).  A recent study monitored urine TCS variability in eight individuals for six days and 
observed high TCS intraclass correlation coefficient (ICC=0.93) and high within individual 
variability (Koch et al., 2014).  A complete 24 hours urine collection may be more adequate in 
capturing the TCS/TCC exposure. Furthermore, multiple urine samples collected between 17 to 
29 weeks reported reasonably good correlation between 0.46 and 0.61 (Bertelsen et al., 2014). 
Therefore, urine samples would be a suitable „gold standard‟ matrix for the validation study. 
Self-report personal care use occurs during EARLI when during early prenatal period and late 
prenatal/early postpartum period.  Questions were asked by an interviewer and subjects reported 
products that they were using.  The early prenatal personal care product use information collected 
during the first home walkthrough represents TCS/TCC product use during 3 months before 
pregnancy until the survey date.  The late prenatal/early postpartum is defined as “since first 
prenatal home visit”, and prenatal and postnatal exposure cannot be separated. Moreover, “since 
first prenatal home visit” could be interpreted as products not including products reported during 
previous home visit. If so, mothers using the same TCC/TCS-containing product as before may 
choose not to report them. Therefore, a validation study of TCS and TCC exposure based on self-
reported personal care product reported during early prenatal period and mother‟s urine collected 
during pregnancy would be most appropriate.  
  
 
Proposed methods 
In the EARLI study, early prenatal urine samples are collected during the enrollment visit and 
first prenatal home visit. Both samples are within the exposure window captured by early prenatal 
questionnaire.  However, urine samples and the questionnaire data that are collected during the 
first prenatal home visit are more likely to have overlapping window of exposure. Multiple urine 
samples, when available, should be used to determine average exposure level, however, urine 
sample from the first home visit should be used if only one sample can be analyzed.  Total TCS 
and TCC, conjugated and unconjugated, should be measured in urine samples.  
Validation study sampling 
Current study focused on increasing the sensitivity of dichotomized TCS/TCC exposure and as a 
result 164 out of 170 subjects were categorized as using any TCS/TCC containing products. 
Therefore, higher variability of TCS/TCC urine level is expected among subjects categorized as 
exposed by the questionnaire data.  Urinary TCS/TCC level is a continuous measure and needs to 
be dichotomized in order to calculate sensitivity, specificity, positive predictive value and 
negative predictive value. Although the best cutoff point would depend on mechanism of 
TCS/TCC action, etiologic mechanism (threshold effect, dose response, etc.) of TCS/TCC and 
autistic trait is largely unknown.  The urinary TCS/TCC level could be dichotomized as above 
and below median.  
 Urinary TCS (above median) Urinary TCS (below median) 
Questionnaire TCS/TCC 
exposure (Yes) 
True Positive False Positive (Type I error) 
Questionnaire TCS/TCC 
exposure (No) 
False Negative (Type II error) True Negative 
 
Other variables of interest 
The time of urine sample collection may play a role in TCS/TCC level because most of the 
TCS/TCC-containing personal care products are used in the morning and night. Therefore, we 
would expect higher urine TCS/TCC levels in the morning. Also, it would be interesting to see if 
  
 
there is variability in urinary TCS/TCC level by cumulative TCS/TCC product use (total number 
of TCS/TCC products used or total number of TCS/TCC category used). In a recent paper, 
subjects using TCS/TCC toothpaste had distinctly higher urinary TCS level (Koch et al., 2014), 
indicating increased buccal absorption compared to dermal absorption. 
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